Synthetic Peptide Catalogue To order or for other enquiries: Email: info@severnbiotech.com    Tel: +44(0)1562-825286    Fax: +44(0)1562-825284 To search this catalogue press Ctrl+F and enter the required information. Alternatively click below. Category List Index Glossary Guidance Notes Catalogue Peptides - Contents Adrenocorticotrophic Hormone (ACTH) and Related Peptides AMPA Type Glutamate Receptor and Related Peptides Amylin (Diabetes Associated Peptide Amide; DAP Amide) and Related Peptides Amyloid ß-Protein Fragments Angiotensin and Related Peptides Atrial Natriuretic Peptide (ANP) and Related Peptides Bombesin and Related Peptides Bradykinin and Related Peptides Brain Natriuretic Peptide (BNP) and Related Peptides Caerulein and Related Peptides Calcitonin and Related Peptides Calcitonin Gene Related Peptide (CGRP) and Related Peptides Caspase Inhibitors Caspase Substrates Cholecystokinin (CCK) and Related Peptides Connexin Peptides Corticotropin Releasing Factor (CRF) and Related Peptides C-Peptide and Related Peptides Dynorphin (Neo-Endorphin) and Related Peptides Endomorphins and Related Peptides Endorphins, Lipotropins, Pro-Opiomelanocortin Fragments and Related Peptides Endothelins and Related Peptides Enkephalin and Related Peptides Enterostatins Exendins and Fragments Fibrinogen Fragments and Related Peptides Fibronectin Fragments and Related Peptides Galanin and Related Peptides Gastric Inhibitory Polypeptide (GIP) and Related Peptides Gastrin and Related Peptides Gastrin Releasing Peptide (GRP) and Related Peptides Ghrelins and Related Peptides Glucagon and Related Peptides Glucagon-Like Peptide (GLP) and Related Peptides Growth Factors and Related Peptides Growth Hormone Releasing Factors (GRF, GHRH) and Related Peptides HIV Related Peptides HPV Peptides Interleukin Fragments and Related Peptides Ion Channel Modulators Leptin Fragments and Related Peptides Luteinizing Hormone Releasing Hormone (LHRH) and Related Peptides Matrix Metalloproteinase (MMP) Substrates Melanocyte Stimulating Hormones (MSH) and Related Peptides Motilin and Related Peptides Myelin Proteins Neurokinins, Neuromedins, Other Tachykinins and Related Peptides Neuropeptide AF and FF, HLWAR77 receptor agonists Neuropeptide Y (NPY) and Related Peptides Neurotensin and Related Peptides Orexins and Related Peptides Oxytocin and Related Peptides Pancreatic Polypeptides (PP) Parathyroid Hormone (PTH) and Related Peptides Peptide YY (PYY) and Related Peptides PHI and PHM Peptides Pituitary Adenylate Cyclase Activating Polypeptides (PACAP) and Related Peptides Prolactin Releasing Peptides (PrRP) and Related Peptides Protease Inhibitors Protease Substrates Protein Kinase Related Peptides Sauvagine and Related Peptides Secretins Somatostatin and Related Peptides Substance P and Related Peptides Substance P Antagonists Thymopoietin (TP) Fragments Thymosin and Fragments Urotensins Vasoactive Intestinal Peptide (VIP) and Related Peptides Vasopressin, Vasotocin and Related Peptides Adrenocorticotrophic Hormone (ACTH) and Related Peptides SBP0001 - ACTH (1-39), human Corticotropin MW: 4541.7 H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu-Ser-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH Review: "ACTH and Related Peptides: Structure, Regulation & Action" (1977) Ann. N.Y. Acad. Sci. 297, 1-641. 500µg 1mg SBP0002 - ACTH (1-24), human Tetracosactide MW: 2933.9 H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-OH Jaquet, Y.F. (1978) Science 291, 1032. 1mg 5mg SBP0003 - ACTH (1-39), porcine MW: 4567.6 H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu-Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 500µg 1mg SBP0004 - [D-Arg8]-ACTH (4-10) MW: 962.2 H-Met-Glu-His-Phe-D-Arg-Trp-Gly-OH This substituted ACTH (4-10) fragment has shown to be an effective MC4 antagonist. Adan RA et al. (1996) Brain Res. Mol. Brain Res. 36, 37 - 44. 5mg 25mg SBP0005 - [Pro8&10,Gly9]-ACTH (4-10) MW: 814.1 H-Met-Glu-His-Phe-Pro-Gly-Pro-OH 5mg 25mg SBP0006 - ACTH (5-10) MW: 830.91 H-Glu-His-Phe-Arg-Trp-Gly-OH 10mg 25mg SBP0007 - ACTH (34-39) MW: 722.9 H-Ala-Phe-Pro-Leu-Glu-Phe-OH 10mg 25mg AMPA Type Glutamate Receptor and Related Peptides SBP0008 - Pep1-TGL MW: 990.14 H-Ser-Ser-Gly-Met-Pro-Leu-Gly-Ala-Thr-Gly-Leu-OH Peptide containing the 'TGL' motif that corresponds to the C terminus of the AMPA receptor GluR1 subunit. Hayashi et al (2000) Science 287 2262 1mg 5mg SBP0009 - Pep1-AGL MW: 960.11 H-Ser-Ser-Gly-Met-Pro-Leu-Gly-Ala-Thr-Gly-Leu-OH Analogue of Pep1-TGL, a peptide containing the 'TGL' motif that corresponds to the C terminus of the AMPA receptor GluR1 subunit. Hayashi et al (2000) Science 287 2262 1mg 5mg SBP0010 - Pep2-AVKI MW: 1268.47 H-Tyr-Asn-Val-Tyr-Gly-Ile-Glu-Ala-Val-Lys-Ile-OH Inhibitor peptide that selectively disrupts binding of the AMPA receptor subunit GluR2 (at the C-terminal PDZ site) to protein interacting with C kinase (PICK1). Does not affect binding of GluR2 to GRIP or ABP and does not increase AMPA current amplitude or affect long term depression (LTD). Li et al (1999) Nature.Neurosci. 2 972. 1mg 5mg SBP0011 - Pep2-EVKI MW: 1326.51 H-Tyr-Asn-Val-Tyr-Gly-Ile-Glu-Glu-Val-Lys-Ile-OH Inhibitor peptide that selectively disrupts binding of the aMPA receptor subunit GluR2 (at the C-terminal PDZ site) to protein interacting with C kinase (PICK1). Does not affect binding of GluR2 to GRIP or ABP and does not increase AMPA current amplitude or affect long term depression (LTD). Li et al (1999) Nature.Neurosci. 2 972. 1mg 5mg SBP0012 - Pep2-SVKI MW: 1284.47 H-Tyr-Asn-Val-Tyr-Gly-Ile-Glu-Ser-Val-Lys-Ile-OH Inhibitor peptide corresponding to last 10 amino acids of the C-terminus of the GluR2 AMPA receptor subunit. Disrupts binding of the GluR2 (at the C-terminal PDZ site) with glutamate receptor interacting protein (GRIP), AMPA receptor binding protein (ABP) and protein interacting with C kinase (PICK1). Increases amplitude of AMPA receptor mediated currents and blocks long-term depression (LTD). Li et al (1999) Nature.Neurosci. 2 972. 1mg 5mg SBP0013 - Pep2-SVKE MW: 1300.43 H-Tyr-Asn-Val-Tyr-Gly-Ile-Glu-Ser-Val-Lys-Glu-OH Inactive control peptide analogue of pep2-SVKI, an inhibitor peptide corresponding to last 10 amino acids of the C-terminus of the GluR2 AMPA receptor subunit. Li et al (1999) Nature.Neurosci. 2 972. 1mg 5mg SBP0014 - Pep2m MW: 1173.44 H-Lys-Arg-Met-Lys-Val-Ala-Lys-Asn-Ala-Gln-OH Peptide inhibitor of the interaction between the C-terminus of the GluR2 (AMPA receptor) subunit and the N-ethylmaleimide-sensitive fusion protein (NSF), a protein that regulates AMPA receptor function. Reduces postsynaptic currentsin CA1 neurons, AMPA-mediated currents in cultured hippocampal neurons and AMPA receptor surface expression. Nishimune et al (1998) Neuron 21 87-97. 1mg 5mg SBP0015 - Pep4c MW: 1146.42 H-Lys-Arg-Met-Lys-Val-Ala-Lys-Ser-Ala-Gln-OH Inactive control peptide analogue of pep2m, an inhibitor of the interaction between the C-terminus of the GluR2 (AMPA receptor) subunit and the N-ethylmaleimide-sensitive fusion protein (NSF), Nishimune et al (1998) Neuron 21 87-97. 1mg 5mg Amylin (Diabetes Associated Peptide Amide; DAP Amide) and Related Peptides SBP0016 - Amylin, human Diabetes-associated Peptide (DAP) Amide, human MW: 3904.1 H-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-Asn-Asn-Phe-Gly-Ala-Ile-Leu-Ser-Ser-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2 (Cys2-7, cyclic) Diabetes-associated peptide (DAP), the C-terminal deaminated form of amylin, was originally isolated from amyloid rich pancreatic tissue of diabetic patients. It also occurs in normal adult islet cells. Amylin inhibits basal and insulin stimulated glucose uptake. Both DAP and amylin are active in vivo and in vitro. Cooper, G.J.S. et al. (1987) Proc. Soc. Natl. Acad. Sci. USA 84, 8628; Westermark, P. et al. (1987) Proc. Soc. Natl. Acad. Sci. 84, 3881. 500µg 1mg SBP0017 - Amylin (8-37), human MW: 3183.9 H-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-Asn-Asn-Phe-Gly-Ala-Ile-Leu-Ser-Ser-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2 Deems, R.O. et al. (1991) Biochem. Biophys. Res. Commun. 181, 116. 500µg 1mg SBP0018 - N-Acetyl-Amylin (8-37), human MW: 3225.9 Ac-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-Asn-Asn-Phe-Gly-Ala-Ile-Leu-Ser-Ser-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2 Very effective antagonist of amylin inhibition of glycogen accumulation. Deems, R.O. et al. (1991) Biochem. Biophys. Res. Commun. 181, 116. 500µg 1mg SBP0019 - Amylin, rat Diabetes-associated Peptide (DAP) Amide, rat MW: 3920.8 H-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-Arg-Ser-Ser-Asn-Asn-Leu-Gly-Pro-Val-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2 (Cys2-7, cyclic) Leffert, J.D. et al. (1989) Proc. Soc. Natl. Acad. Sci. 86, 3127 500µg 1mg SBP0020 - Amylin (8-37), rat MW: 3200.8 H-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-Arg-Ser-Ser-Asn-Asn-Leu-Gly-Pro-Val-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2 Deems, R.O. et al. (1991) Biochem. Biophys. Res. Commun. 181, 116. 500µg 1mg SBP0021 - N-Acetyl-Amylin (8-37), rat MW: 3242.6 Ac-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-Arg-Ser-Ser-Asn-Asn-Leu-Gly-Pro-Val-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2 Very effective antagonist of amylin action on glycogen accumulation. Deems, R.O. et al. (1991) Biochem. Biophys. Res. Commun. 181, 116. 500µg 1mg SBP0022 - proIAPP MW: 7401.43 H-Thr-Pro-Ile-Glu-Ser-His-Gln-Val-Glu-Lys-Arg-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-Asn-Asn-Phe-Gly-Ala-Ile-Leu-Ser-Ser-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-Gly-Lys-Arg-Asn-Ala-Val-Glu-Val-Leu-Lys-Arg-Glu-Pro-Leu-Asn-Tyr-Leu-Pro-Leu-OH This 67-mer is the pre-pro-protein for amylin, human. 500µg 1mg Amyloid ß-Protein Fragments SBP0023 - Amyloid ß-Protein (1-43) MW: 4615.21 H-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala-Thr-OH The amyloid ß-protein consists of a 39-43 amino-acid polypeptide and is the primary constituent of senile plaques and cerebrovascular deposits in Alzheimer's disease and Down's Syndrome. Is additionally acts as an inhibitor of the Ubiquitin dependant protein degradation in vitro. Kang, J. et al. (1987) Nature 325, 733; Goldgaber, D. et al. (1987) Science 235, 877; Murrell, J. et al. (1991) Science 254, 97; Pike, C.J. et al. (1994) Neuroscience 63, 517. 500µg 1mg SBP0024 - Amyloid ß-Protein (1-42) MW: 4514.1 H-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala-OH This 42-amino acid peptide is the predominant form of amyloid beta-protein in the brains of Alzheimer patients. Kang, J. et al. (1987) Nature 325, 733; Goldgaber, D. et al. (1987) Science 235, 877; Murrell, J. et al.(1991) Science 254, 97; Pike, C.J. et al. (1994) Neuroscience 63, 517. 500µg 1mg SBP0025 - Amyloid ß-Protein (1-40) MW: 4329.8 H-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-OH This peptide has been demonstrated to possess both neurotrophic and neurotoxic activities. Yankner et al. (1990) Science 250, 279; Maggio, J.E. et al. (1992) Proc. Soc. Natl. Acad. Sci. 89, 5462. 500µg 1mg SBP0026 - Amyloid ß-Protein (25-35) MW: 1060.6 H-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-OH Fragment with neurotrophic and neurotoxic activities. Yankner et al. (1990) Science 250, 279; Klegeris, A. et al. (1994) Biochem. Biophys. Res. Commun. 199, 984; Pike, C.J. et al. (1994) Neuroscience 63, 517; Pike, C.J. et al. (1995) J. Neurochem. 64, 253. 1mg 5mg SBP0027 - Amyloid Precursor Protein ß-Secretase Inhibitor MW: 1651.8 H-Lys-Thr-Glu-Glu-Ile-Ser-Glu-Val-Asn-Sta-Val-Ala-Glu-Phe-OH This statin analogue of an amyloid precursor protein fragment is an effective inhibitor of ß-secretase from human brain. ß-secretase is responsible for proteolytic cleavage of N-terminal fragment from amyloid precursor protein between residues 671 and 672, leading to the generation of the soluble form of amyloid precursor protein. The C-terminal fragment is further processed by gamma-secretase to form the amyloid ß-peptide assumed to be the pathological component of Alzheimers's disease. Sinha S. et al. (1999) Nature 402, 537. 1mg 5mg Angiotensin and Related Peptides SBP0028 - Angiotensin I, human (Decapeptide) MW: 1296.7 H-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-OH The above sequence has been shown to be common to the human, horse, sheep, pig and rat species. Felix, D. et al. (1991) Hypertension 6, 111. 25mg 100mg SBP0029 - Angiotensin II, human (Octapeptide) MW: 1046.3 H-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH The above sequence has been shown to be common to the human, horse, sheep, pig and rat species. Inagami, T. et al. (1988) Cardiovascular Drugs Therap. 2, 453. 25mg 100mg SBP0030 - [Des-Leu10]-Angiotensin I Angiotensin I (1-9) MW: 1183.5 H-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-OH 5mg 25mg SBP0031 - [Sar1]-Angiotensin II MW: 1002.3 H-Sar-Arg-Val-Tyr-Ile-His-Pro-Phe-OH Hall, M.M. et al. (1973) J. Pharm. Exp. Ther. 188, 222; Mendelsohn, F.A.O. et al. (1984) Proc. Soc. Natl. Acad. Sci. USA 81, 1575. 5mg 25mg SBP0032 - [Asn1,Val5]-Angiotensin II MW: 1031.5 NH2-Asn-Arg-Val-Tyr-Val-His-Pro-Phe-OH The native form of angiotensin II in teleost fish Olsen K.R. (1992) Fish Physiology XII . B. The Cardiovascular System, pp 136-232. Academic Press (Eds.: WS Hoar, DJ Randall, AP Farrell), Olsen K.R. et al. (1992) J. Exptl. Biol. 194, 117. 25mg 100mg Atrial Natriuretic Peptide (ANP) and Related Peptides SBP0033 - Atrial Natriuretic Peptide (1-28), human, porcine ANF (1-28), human, porcine MW: 3080.9 H-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH (Cys7-23, cyclic) Kangawa, K. et al. (1984) Biochem. Biophys. Res. Commun. 118, 131. 500µg 1mg SBP0034 - Atrial Natriuretic Peptide (1-28), rat ANF (1-28), rat MW: 3062.9 H-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH (Cys7-23,cyclic) Flynn, T.G. et al. (1983) Biochem. Biophys. Res. Commun. 117, 859. 500µg 1mg SBP0035 - Thr-Ala-Pro-Arg-ANP, human Urodilatin MW: 3506.5 H-Thr-Ala-Pro-Arg-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH (Cys11-27, cyclic) Gagelmann, M et al. (1988) FEBS Letters 233, 249. 500µg 1mg Bombesin and Related Peptides SBP0036 - Bombesin MW: 1620.1 pGlu-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2 Anastasi, A. et al. (1971) Experientia 27, 166; Bertaccini, G. et al. (1974) Br. J. Pharmacol. 52, 219 and 227; Brown, M. et al. (1977) Science 196, 998. 5mg 25mg SBP0037 - [Leu13-ψ(CH2NH)-Leu14]-Bombesin MW: 1587.9 pGlu-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-ψ(CH2NH)-Leu-NH2 Bombesin Receptor Antagonist Cowan, A. et al. (1988) TIPS 9, 1; Coy, D.H. et al. (1988) J. Biol. Chem. 263, 5056. 500µg 1mg SBP0038 - [D-Phe6, ß-Ala11, Phe13, Nle14]-Bombesin (6-14) MW: 1117.4 H-D-Phe-Gln-Trp-Ala-Val-ß-Ala-His-Phe-Nle-NH2 This bombesin analogue has been found to be a high affinity ligand for the human orphan receptor, bombesin receptor subtype 3 (BRS-3). Neither bombesin itself nor any of its analogues that bind to other bombesin receptor subtypes exhibited significant affinity for BRS-3. Binding of this peptide to BRS-3 stimulates the formation of inositol phosphates. Guanosine 5'-(ß,-imido)-triphosphate causes a change in receptor affinity, preventing binding of this ligand. These results indicate that for a member of the bombesin receptor family, BRS-3 has a unique pharmacological profile. The natural ligand for the BRS-3 receptor subtype is presumably either an undiscovered member of the bombesin family or an unrelated peptide. Mantey, S.A. et al. (1997) J. Biol. Chem. 272, 26062. 1mg 5mg SBP0039 - [D-Tyr6,ß-Ala11, Phe13,Nle14]-Bombesin (6-14) MW: 1133.3 H-D-Tyr-Gln-Trp-Ala-Val-ß-Ala-His-Phe-Nle-OH Tapas K.P. et al. (1998) Eur. J. Pharmacol. 343, 275. 1mg 5mg SBP0040 - Alytesin MW: 1535.78 pGlu-Gly-Arg-Leu-Gly-Thr-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2 Amphibian bombesin like peptide. In vivo stimulates gastric acid secretion, intestinal contraction, rat uterine contraction and hypertension in the dog. Also modulates thermoregulation following central administration in vivo. Anastasi, A. et al. (1971) Experientia 27, 166; Bertaccini, G. et al. (1974) Br. J. Pharmacol. 52, 219 and 227; Brown, M. et al. (1977) Science 196, 998. 5mg 25mg Bradykinin and Related Peptides SBP0041 - Bradykinin MW: 1060.3 H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Regoli, D. & Barabe, J. (1980) Pharmacol. Rev. 32, 1; Okamoto, H. et al. (1985) Biochem. Biophys. Res. Commun. 112, 701; Barlas, A. (1985) Biochem. Biophys. Res. Commun. 129, 280. 25mg 100mg SBP0042 - [Des-Arg9,Lys0]-Bradykinin [Des-Arg10]-Kallidin MW: 1032.3 H-Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-OH 10mg 25mg Brain Natriuretic Peptide (BNP) and Related Peptides SBP0043 - Brain Natriuretic Peptide, human BNP-32, human MW: 3464.6 H-Ser-Pro-Lys-Met-Val-Gln-Gly-Ser-Gly-Cys-Phe-Gly-Arg-Lys-Met-Asp-Arg-Ile-Ser-Ser-Ser-Ser-Gly-Leu-Gly-Cys-Lys-Val-Leu-Arg-Arg-His-OH (Cys10-26, cyclic) Sudoh, T. et al. (1988) Nature 332, 78; Sudoh, T. et al. (1989) Biochem. Biophys. Res. Commun. 159, 1427. 500µg 1mg Caerulein and Related Peptides SBP0044 - Caerulein, non-sulphated MW: 1271.5 pGlu-Gln-Asp-Tyr-Thr-Gly-Trp-Met-Asp-Phe-NH2 1mg 5mg SBP0045 - Caerulein, sulphated MW: 1351.5 pGlu-Gln-Asp-Tyr(SO4H)-Thr-Gly-Trp-Met-Asp-Phe-NH2 Anastasi, A. et al. (1967) Experientia 23, 699. 1mg 5mg Calcitonin and Related Peptides SBP0046 - Calcitonin, eel MW: 3415.4 H-Cys-Ser-Asn-Leu-Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asp-Val-Gly-Ala-Gly-Thr-Pro-NH2 (Cys1-7, cyclic) 1mg 5mg SBP0047 - Calcitonin, human MW: 3418.4 H-Cys-Gly-Asn-Leu-Ser-Thr-Cys-Met-Leu-Gly-Thr-Tyr-Thr-Gln-Asp-Phe-Asn-Lys-Phe-His-Thr-Phe-Pro-Gln-Thr-Ala-Ile-Gly-Val-Gly-Ala-Pro-NH2 (Cys1-7, cyclic) Nakagawa, Y. et al. (1977) Peptide Chemistry p. 189. 1mg 5mg SBP0048 - Calcitonin, rat MW: 3400.4 H-Cys-Gly-Asn-Leu-Ser-Thr-Cys-Met-Leu-Gly-Thr-Tyr-Thr-Gln-Asp-Leu-Asn-Lys-Phe-His-Thr-Phe-Pro-Gln-Thr-Ser-Ile-Gly-Val-Gly-Ala-Pro-NH2 (Cys1-7, cyclic) Byfield, P.G.H et al. (1976) FEBS Letters 65, 242. 1mg 5mg SBP0049 - Calcitonin, salmon MW: 3432.4 H-Cys-Ser-Asn-Leu-Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro-NH2 (Cys1-7, cyclic) Hamilton, C.R. (1974) Am. J. Med. 56, 858 1mg 5mg Calcitonin Gene Related Peptide (CGRP) and Related Peptides SBP0050 - CGRP, chicken MW: 3838.9 H-Ala-Cys-Asn-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Asp-Phe-Leu-Ser-Arg-Ser-Gly-Gly-Val-Gly-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH2 (Cys2-7, cyclic) Minvielle, S. et al. (1986) FEBS Letters 203, 7. 500µg 1mg SBP0051 - α-CGRP, human CGRP-1, human MW: 3789.9 H-Ala-Cys-Asp-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH2 (Cys2-7, cyclic) Morris, H.R. et al. (1984) Nature 308, 746; Le Greves, P. et al. (1985) Eur. J. Pharmacol. 115, 309; Davies, D. et al. (1992) Biochem. Pharm. 43, 1753; Henke, H. et al. (1987) Brain Res. 410, 404. 500µg 1mg SBP0052 - [Cys(Acm)2&7]-α-CGRP, human MW: 3934.2 H-Ala-Cys(Acm)-Asp-Thr-Ala-Thr-Cys(Acm)-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH2 500µg 1mg SBP0053 - [Cys(Et)2&7]-α-CGRP, human MW: 3848 H-Ala-Cys(Et)-Asp-Thr-Ala-Thr-Cys(Et)-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH2 This peptide is a potent CGRP-2 receptor agonist. The CGRP alpha analogue exhibits a high potency to inhibit the rat vas deferens twitch response, but induces only a slight inotropic effect in guinea pig atrium even at very high concentrations. It also competes with labelled hCGRP alpha with high affinity for binding sites in rat brain homogenates. These results suggest that this analogue will be valuable in assessing the functional relevance of CGRP-2 receptors. Dumont et al. (1997) Can. J. Physiol.Pharmacol. 75, 671-676. 500µg 1mg SBP0054 - α-CGRP (8-37), human MW: 3126.1 H-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH2 CGRP receptor antagonist Chiba, T. et al. (1989) Am. J. Physiol. 256, E331; Hao, H. et al. (1993) Neuropeptides 26, 123. 500µg 1mg SBP0055 - α-CGRP, rat MW: 3806.9 H-Ser-Cys-Asn-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asp-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Glu-Ala-Phe-NH2 (Cys2-7, cyclic) Rosenfeld, M.G. et al. (1983) Nature 304, 129. 500µg 280.00 140.00 140.00 1mg 500.00 250.00 250.00 SBP0056 - [Tyr22]-α-CGRP (22-37), rat MW: 1786.2 H-Tyr-Val-Lys-Asp-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Glu-Ala-Phe-NH2 CGRP fragment suitable for radiolabelling as ligand for immunoassay. Rosenfeld, M.G. et al. (1983) Nature 304, 129. 1mg 5mg SBP0057 - CGRP (32-37), rat MW: 607.7 Val-Gly-Ser-Glu-Ala-Phe-NH2 CCK receptor antagonist 1mg 5mg Caspase Inhibitors SBP0058 - Caspase 1 Inhibitor Ac-YVAD aldehyde MW: 492.5 Ac-Tyr-Val-Ala-Asp-CHO A specific reversible inhibitor of caspase 1 (ICE, Interleukin 1ß Converting Enzyme) Thornberry N.A. et al. (1992) Nature 356, 768; Molineaux S.M. et al. (1993) Proc. Natl. Acad. Sci. USA 90, 1809; Walker N.P.C. et al. (1994) Cell 78, 343; Wilson K.P. et al. (1994) Nature 370, 270; Enari M. et al. (1996) Nature 380, 723. 5mg 25mg SBP0059 - Caspase 3 Inhibitor Ac-DEVD aldehyde MW: 502.5 Ac-Asp-Glu-Val-Asp-CHO A potent inhibitor of caspase 3 (Apopain). The peptide aldehyde has been shown to attenuate apoptosis in vitro. Nicholson D.W. et al. (1995) Nature 376, 37; Enari M. et al. (1996) Nature 380, 723. 5mg 25mg SBP0060 - Caspase 6 Inhibitor Ac-VEID aldehyde MW: 500.5 Ac-Val-Glu-Ile-Asp-CHO A specific inhibitor of caspase 6 (Mch2). 5mg 25mg SBP0061 - Caspase 8 Inhibitor Ac-IETD aldehyde MW: 502.5 Ac-Ile-Glu-Thr-Asp-CHO A caspase 8 inhibitor. Han Z. et al. (1997) J. Biol. Chem. 272, 13432. 5mg 25mg Caspase Substrates SBP0062 - Chromogenic Caspase 4 Substrate Ac-LEVD-pNA MW: 636.7 Ac-Leu-Glu-Val-Asp-pNA Chromogenic substrate for caspase 4 (ICH-2) Talanian R. et al. (1997) J. Biol. Chem. 272, 9677. 5mg 25mg SBP0063 - Chromogenic Caspase 3 Substrate Ac-DEVD-pNA MW: 638.6 Ac-Asp-Glu-Val-Asp-pNA 5mg 25mg SBP0064 - Fluorogenic Caspase 1 Substrate Ac-YEVD-AMC MW: 723.7 Ac-Tyr-Glu-Val-Asp-AMC Fluorogenic substrate for caspase 1 (ICE). Talanian R. et al. (1997) J. Biol. Chem. 272, 9677. 5mg 25mg SBP0065 - Fluorogenic Caspase 1 Substrate Ac-YVAD-AMC Interleukin 1ß Converting Enzyme Substrate II MW: 665.7 Ac-Tyr-Val-Ala-Asp-AMC Fluorogenic substrate for caspase 1 (ICE). Thornberry N.A. et al. (1992) Nature 356, 768; Walker N.P.C. et al. (1994) Cell 78, 343. 5mg 25mg SBP0066 - Caspase 3 Substrate Ac-DEVD-AMC MW: 675.5 Ac-Asp-Glu-Val-Asp-AMC A useful fluorogenic caspase-3 substrate Nicholson, D.W. et al. (1995) Nature 376, 37. 5mg 25mg SBP0067 - Fluorogenic Caspase 6 Substrate Ac-VEID-AMC MW: 673.7 Ac-Val-Glu-Ile-Asp-AMC Fluorogenic substrate for caspase 6 (Mch2) Takahashi A. et al. (1996) Proc. Natl. Acad. Sci. USA 93, 8395; Martins L.M. et al. (1997) J. Biol. Chem. 272, 7421; Nagata S. (1997) Cell 88, 355; Talanian R. et al. (1997) J. Biol. Chem. 272, 9677. 5mg 25mg SBP0068 - Fluorogenic Caspase 3 Substrate Ac-DEVD-AFC MW: 729.6 Ac-Asp-Glu-Val-Asp-AFC 5mg 25mg SBP0069 - Fluorogenic Caspase 8 Substrate Ac-IETD-AMC MW: 675.7 Ac-Ile-Glu-Thr-Asp-AMC Fluorogenic substrate for caspase 8. 5mg 25mg Cholecystokinin (CCK) and Related Peptides SBP0070 - Cholecystokinin (26-33), non-sulphated CCK Octapeptide (CCK-8), non-sulphated MW: 1063.3 H-Asp-Tyr-Met-Gly-Trp-Met-Asp-Phe-NH2 1mg 5mg SBP0071 - Cholecystokinin (26-33), sulphated CCK Octapeptide (CCK-8), sulphated MW: 1143.3 H-Asp-Tyr(SO4H)-Met-Gly-Trp-Met-Asp-Phe-NH2 Ondetti, M.A. et al. (1970) J. Am. Chem. Soc. 92, 195 1mg 5mg Connexin Peptides SBP0306 - Gap18 MW: 1834.18 H-Met-Gly-Asp-Trp-Ser-Ala-Leu-Gly-Lys-Leu-Leu-Asp-Lys-Val-Gln-Ala-Cys-OH Analogue of intracellular amino-terminal tail of connexin 43. 1mg 5mg SBP0307 - Gap 20 MW: 1114.36 H-Glu-Ile-Lys-Lys-Phe-Lys-Tyr-Gly-Cys-OH Analogue of intracellular loop of connexin 43. 1mg 5mg SBP0072 - Gap 26 MW: 1549.81 H-Val-Cys-Tyr-Asp-Lys-Ser-Phe-Pro-Ile-Ser-His-Val-Arg-OH Analogue of extracellular loop 1 of connexin 43. Gap junction blocker. 1mg 5mg SBP0073 - Gap 26 Scrambled MW: 1549.81 H-Pro-Ser-Phe-Asp-Ser-Arg-His-Cys-Ile-Val-Lys-Tyr-Val-OH Inactive experimental control. 1mg 5mg SBP0074 - Gap 27 Cx37,43 MW: 1304.56 H-Ser-Arg-Pro-Thr-Glu-Lys-Thr-Ile-Phe-Ile-Ile-OH Analogue of extracellular loop 2 of connexins 37 and 43. Gap junction blocker. 1mg 5mg SBP0075 - Gap 27 Cx37,43 Scrambled MW: 1304.56 H-Thr-Phe-Glu-Pro-Ile-Arg-Ile-Ser-Ile-Thr-Lys-OH Inactive experimental control. 1mg 5mg SBP0076 - Gap 27 Cx40 MW: 1289.51 H-Ser-Arg-Pro-Thr-Glu-Lys-Asn-Val-Phe-Ile-Val-OH Analogue of extracellular loop 2 of connexin40. Gap junction blocker. 1mg 5mg SBP0077 - Gap 27 Cx40 Scrambled MW: 1289.51 H-Thr-Phe-Glu-Pro-Val-Arg-Val-Ser-Ile-Asn-Lys-OH Inactive experimental control. 1mg 5mg Corticotropin Releasing Factor (CRF) and Related Peptides SBP0078 - Corticotropin Releasing Factor, bovine MW: 4697.9 H-Ser-Gln-Glu-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Met-Thr-Lys-Ala-Asp-Gln-Leu-Ala-Gln-Gln-Ala-His-Asn-Asn-Arg-Lys-Leu-Leu-Asp-Ile-Ala-NH2 Esch, F. et al. (1984) Biochem. Biophys. Res. Commun. 122, 899. 500µg 1mg SBP0079 - Corticotropin Releasing Factor, human, rat MW: 4758.1 H-Ser-Glu-Glu-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Met-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Gln-Ala-His-Ser-Asn-Arg-Lys-Leu-Met-Glu-Ile-Ile-NH2 Shibahara, S. et al. (1983) EMBO J. 2, 775. 500µg 1mg SBP0080 - [Tyr0]-Corticotropin Releasing Factor, human, rat MW: 4921.3 H-Tyr-Ser-Glu-Glu-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Met-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Gln-Ala-His-Ser-Asn-Arg-Lys-Leu-Met-Glu-Ile-Ile-NH2 500µg 1mg SBP0081 - Corticotropin Releasing Factor (6-33) Amide, human, rat MW: 3220.5 H-Ile-Ser-Leu-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Met-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Gln-Ala-His-Ser-NH2 CRF(6-33) is a CRF fragment, which does not bind to CRF receptors. However, it does bind to CRF-BP (CRF binding protein) and, by displacing biologically active ligands from CRF-BP, it can effectively increase the levels of free CRF and urocortin in the brain. Sutton, S.W. et al. (1995) Endocrinology 136, 1097; Behan, P. et al. (1995) Nature 378, 284. 500µg 1mg SBP0082 - [D-Phe12, Nle21&38, C-α-Me-Leu37]-CRF (12-41), human, rat MW: 3553.6 H-D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Gln-Ala-His-Ser-Asn-Arg-Lys-a-Me-Leu-Nle-Glu-Ile-Ile-NH2 CRF Antagonist Hernandez, J.-F. et al. (1993) J. Med. Chem. 36, 2860; de Fonseca, F.R. et al. (1996) J. Pharmacol. Exp. Therap. 276, 56. 500µg 1mg SBP0083 - [D-Phe12, Nle21&38, cyclo-{Glu30-Lys33}]-CRF (12-41), cyclic lactam, human, rat Astressin MW: 3563.7 H-D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Glu-Ala-His-Lys-Asn-Arg-Lys-Leu-Nle-Glu-Ile-Ile-NH2 (Glu19-Lys22, cyclic lactam) Gulyas et al. (1995) PNAS.USA 92, 10575 500µg 1mg SBP0084 - Corticotropin Releasing Factor, ovine MW: 4671 H-Ser-Gln-Glu-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Met-Thr-Lys-Ala-Asp-Gln-Leu-Ala-Gln-Gln-Ala-His-Ser-Asn-Arg-Lys-Leu-Leu-Asp-Ile-Ala-NH2 Vale, W. et al. (1981) Science 213, 1394. 500µg 1mg SBP0085 - α-Helical CRF (9-41) MW: 3826.9 H-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-Met-Leu-Glu-Met-Ala-Lys-Ala-Glu-Gln-Glu-Ala-Glu-Gln-Ala-Ala-Leu-Asn-Arg-Leu-Leu-Leu-Glu-Glu-Ala-NH2 CRF Antagonist Rivier, J. et al. (1984) Science 224, 889. 500µg 1mg SBP0086 - α-Helical CRF (12-41) MW: 3497.6 H-Phe-His-Leu-Leu-Arg-Glu-Met-Leu-Glu-Met-Ala-Lys-Ala-Glu-Gln-Glu-Ala-Glu-Gln-Ala-Ala-Leu-Asn-Arg-Leu-Leu-Leu-Glu-Glu-Ala-NH2 CRF Antagonist 500µg 1mg SBP0087 - Urocortin, human MW: 4696.8 H-Asp-Asn-Pro-Ser-Leu-Ser-Ile-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Thr-Leu-Leu-Glu-Leu-Ala-Arg-Thr-Gln-Ser-Gln-Arg-Glu-Arg-Ala-Glu-Gln-Asn-Arg-Ile-Ile-Phe-Asp-Ser-Val-NH2 Following the discovery of urocortin in rat brain, the human peptide was cloned. Human and rat urocortin show 95% sequence homology. Human urocortin has been shown to bind to CRF-1, CRF-2alpha and CRF-2beta receptors as well as CRF-BP. Urocortin is reported to be more effective at suppressing appetite than CRF, but less potent at producing anxiety-like effects. Donaldson et al. (1996), Endocrinology 137, 2167; Spina et al. (1996) Science 273, 1561. 500µg 1mg SBP0088 - Urocortin, rat MW: 4707.8 H-Asp-Asp-Pro-Pro-Leu-Ser-Ile-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Thr-Leu-Leu-Glu-Leu-Ala-Arg-Thr-Gln-Ser-Gln-Arg-Glu-Arg-Ala-Glu-Gln-Asn-Arg-Ile-Ile-Phe-Asp-Ser-Val-NH2 Urocortin is a 40 amino acid peptide originally discovered in rat brain. It is a member of the CRF familiy which also includes the frog peptide sauvagine and the fish peptide urotensin. Indeed, urocortin shows a closer sequence homology to urotensin (63%) than to CRF (45%). Urocortin binds more effectively to CRF Type 2 receptors than CRF itself and is probably the endogenous ligand. Vaughan et al. (1995) Nature 378, 287 500µg 1mg C-Peptide and Related Peptides SBP0089 - C-Peptide (1-35), human Proinsulin (31-65), human MW: 3617.1 H-Arg-Arg-Glu-Ala-Glu-Asp-Leu-Gln-Val-Gly-Gln-Val-Glu-Leu-Gly-Gly-Gly-Pro-Gly-Ala-Gly-Ser-Leu-Gln-Pro-Leu-Ala-Leu-Glu-Gly-Ser-Leu-Gln-Lys-Arg-OH IMPORTANT - Possible confusion on C-Peptide nomenclature: During the cleavage of proinsulin, the N- and C-terminal dipeptide sequences are clipped from the 35-amino acid sequence, proinsulin (31-65), which connects the insulin A and B chains in proinsulin. The designations "Connecting Peptide" and "C-Peptide" have been used in the past to refer to both the 35-amino acid sequence given above and to the 31 amino acid sequence, C-Peptide (3-33), syn. Proinsulin (33-63), which is the circulating form present in blood. Please ensure that you order only the sequence you require. For C-Peptide (3-33). Ko, A.S.C. & Smyth, D.G. (1971) Eur. J. Biochem. 20, 190; Oyer, P.E. et al. (1971) J. Biol. Chem. 246, 1375; Frank et al. (1981) Proc. 7th Am. Peptide Symp. p. 729 500µg 1mg SBP0090 - [Tyr0]-C-Peptide (1-35), human Tyr-Proinsulin (31-65), human MW: 3780.3 H-Tyr-Arg-Arg-Glu-Ala-Glu-Asp-Leu-Gln-Val-Gly-Gln-Val-Glu-Leu-Gly-Gly-Gly-Pro-Gly-Ala-Gly-Ser-Leu-Gln-Pro-Leu-Ala-Leu-Glu-Gly-Ser-Leu-Gln-Lys-Arg-OH 500µg 1mg SBP0091 - C-Peptide (3-33), human Proinsulin (33-63), human MW: 3020.7 H-Glu-Ala-Glu-Asp-Leu-Gln-Val-Gly-Gln-Val-Glu-Leu-Gly-Gly-Gly-Pro-Gly-Ala-Gly-Ser-Leu-Gln-Pro-Leu-Ala-Leu-Glu-Gly-Ser-Leu-Gln-OH Recent reports indicate that this peptide may be biologically active and may stimulate insulin secretion. Prolonged administration of C-Peptide to IDDM patients leads to improved renal and autonomic nervous function. IMPORTANT - Possible confusion on C-Peptide nomenclature: During the cleavage of proinsulin, the N- and C-terminal dipeptide sequences are clipped from the 35-amino acid sequence, proinsulin (31-65), which connects the insulin A and B chains in proinsulin. The designations "Connecting Peptide" and "C-Peptide" have been used in the past to refer to both the 31-amino acid sequence given above, which is the circulating form present in blood, and to the 35 amino acid sequence, C-Peptide (1-35), syn. Proinsulin (31-65). Please ensure that you order only the sequence you require. For C-Peptide (1-35). Ko, A.S.C. & Smyth, D.G. (1971) Eur. J. Biochem. 20, 190; Oyer, P.E. et al. (1971) J. Biol. Chem. 246, 1375; Igano et al. (1981) Bull. Chem. Soc. Japan 54, 3088; Wahren et al. (1996) J. Internal Med. 240, 115. 500µg 1mg SBP0092 - C-Peptide (3-35), human Proinsulin (33-65), human MW: 3305.1 H-Glu-Ala-Glu-Asp-Leu-Gln-Val-Gly-Gln-Val-Glu-Leu-Gly-Gly-Gly-Pro-Gly-Ala-Gly-Ser-Leu-Gln-Pro-Leu-Ala-Leu-Glu-Gly-Ser-Leu-Gln-Lys-Arg-OH IMPORTANT - Possible confusion on C-Peptide nomenclature: During the cleavage of proinsulin, the N- and C-terminal dipeptide sequences are clipped from the 35-amino acid sequence, proinsulin (31-65), which connects the insulin A and B chains in proinsulin. The designations "Connecting Peptide" and "C-Peptide" have been used in the past to refer to both the 31-amino acid sequence , which is the circulating form present in blood, and to the 35 amino acid sequence, C-Peptide (1-35), syn. Proinsulin (31-65). Please ensure that you order only the sequence you require. 500µg 1mg Dynorphin (Neo-Endorphin) and Related Peptides SBP0093 - Dynorphin A Prodynorphin (207-223), human; Prodynorphin (209-225), porcine MW: 2147.8 H-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln-OH Goldstein, A. et al. (1981) Proc. Soc. Natl. Acad. Sci. US 78, 7219; Tachibana, S. et al. (1982) Nature 295, 339; Horikawa, S. et al. (1983) Nature 306, 611. 1mg 5mg SBP0094 - Dynorphin A (1-13) MW: 1604.3 H-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-OH Goldstein, A. et al. (1988) Proc. Soc. Natl. Acad. Sci. USA 76, 6666; Rabkin, S.W. (1992) Regulatory Peptides 41, 95; Kameyama, T. et al. (1994) Neurpharmacology 33, 1167. 1mg 5mg SBP0095 - [Arg11&13]-Dynorphin A (1-13)-Gly-NH(CH2)5NH2 DAKLI MW: 1801.5 H-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Arg-Leu-Arg-Gly-NH(CH2)5NH2 Dynorphin A analog kappa ligand. Goldstein, A. et al. (1988) Proc. Soc. Natl. Acad. Sci. USA 85, 7375. 500µg 1mg SBP0096 - Dynorphin B Rimorphin MW: 1571.1 H-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr-OH Fischli, W. et al. (1982) Proc. Soc. Natl. Acad. Sci. USA 79, 5435; Kilpatrick, D. et al. (1982) Life Science 31, 1849; Simpson, J.N. et al. (1992) Neuroscience Letters 137, 149. 500µg 1mg SBP0097 - Nociceptin Orphanin FQ MW: 1809.4 H-Phe-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Leu-Ala-Asn-Gln-OH Meunier, J.-C. et al. (1995) Nature 377, 532; Shimohigashi, Y. et al. (1996) J. Biol. Chem. 271, 23642. 1mg 5mg SBP0098 - Nociceptin (1-13) Amide MW: 1381.6 H-Phe-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-NH2 This nociceptin fragment is reported to be the smallest fragment still retaining full efficacy and potency in the mouse vas deferens and guinea pig ileum bioassays. Calo, G. et al. (1996) Eur. J. Pharmacol. 311, R3-R5; Guerrini, R. et al. (1997) J. Med. Chem. 40, 1789.; Calo, G. et al. (1997) Can. J. Physiol. Pharmacol. 75, 713. 5mg 25mg SBP0099 - [Phe1-ψ(CH2-NH)-Gly2]-Nociceptin (1-13) Amide MW: 1367.6 H-Phe-ψ(CH2-NH)-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-NH2 This peptide is a competitive antagonist of nociceptin. Guerrini et al. (1998) Br. J. Pharmacol. 123, 163. 500µg 1mg Endomorphins and Related Peptides SBP0100 - Endomorphin-1 MW: 610.7 H-Tyr-Pro-Trp-Phe-NH2 Endomorphin-1 is a tetrapeptide peptide isolated from the mammalian brain that exhibits an exceptionally high specificity for the µ-opiate receptor and may well be a natural ligand for this receptor. It induces prolonged and potent analgesia in mice. Zadina et al. (1997) Nature 386, 499 5mg 25mg SBP0101 - Endomorphin-2 MW: 571.7 H-Tyr-Pro-Phe-Phe-NH2 Endomorphin-2 is an endogenous analogue of endomorphin-1 and may also be a natural ligand for the µ-opiate receptor. Zadina et al. (1997) Nature 386, 499 5mg 25mg Endorphins, Lipotropins, Pro-Opiomelanocortin Fragments and Related Peptides SBP0102 - ß-Endorphin, human ß-Lipotropin (61-91), human MW: 3465.6 H-Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-Ile-Ile-Lys-Asn-Ala-Tyr-Lys-Lys-Gly-Glu-OH Li, C.H. et al. (1977) J. Med. Chem. 20, 325. 1mg 5mg SBP0103 - ß-Endorphin, porcine MW: 3424.8 H-Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-Ile-Val-Lys-Asn-Ala-His-Lys-Lys-Gly-Gln-OH 500µg 1mg Endothelins and Related Peptides SBP0104 - Big Endothelin-1, human MW: 4283.6 H-Cys-Ser-Cys-Ser-Ser-Leu-Met-Asp-Lys-Glu-Cys-Val-Tyr-Phe-Cys-His-Leu-Asp-Ile-Ile-Trp-Val-Asn-Thr-Pro-Glu-His-Val-Val-Pro-Tyr-Gly-Leu-Gly-Ser-Pro-Arg-Ser-OH (Cys1-15, Cys3-11, dicyclic) Itoh et al. (1988) FEBS Letters 231, 440 500µg 1mg SBP0105 - Endothelin 1, dog, human, porcine, rat MW: 2492.2 H-Cys-Ser-Cys-Ser-Ser-Leu-Met-Asp-Lys-Glu-Cys-Val-Tyr-Phe-Cys-His-Leu-Asp-Ile-Ile-Trp-OH (Cys1-15, Cys3-11, dicyclic) Itoh, Y. et al. (1988) FEBS Letters 231, 440; Yanagisawa, M. et al. (1988) Nature 332, 411 500µg 1mg SBP0106 - N-Succinyl-[Glu9, Ala11&15]-Endothelin (8-21) IRL 1620 MW: 1821.2 Suc-Asp-Glu-Glu-Ala-Val-Tyr-Phe-Ala-His-Leu-Asp-Ile-Ile-Trp-OH Endothelin ET-B receptor antagonist Takai et al. (1992) Biochem. Biophys. Res. Commun. 184, 953. 500µg 1mg SBP0107 - BQ123 MW: 610.8 Cyclo(D-Asp-Pro-D-Val-Leu-D-Trp) Endothelin antagonist selective for ET-A receptor subtype. Atkinson, R.A. & Pelton, J.T. (1992) FEBS Letters 296, 1; Eguchi, S. et al. (1992) FEBS Letters 302, 243; Ihara, M. et al. (1992) Life Science 50, 247; Hiley, C.R. et al. (1992) Biochem. Biophys. Res. Commun. 184, 504; Ohlstein, E.H. et al. (1992) Eur. J. Pharmacol. Mol. 225, 347; Webb, M.L. et al. (1992) Biochem. Biophys. Res. Commun. 185, 887. 1mg 5mg Enkephalin and Related Peptides SBP0108 - [Leu5]-Enkephalin Dynorphin A (1-5); a-Neoendorphin (1-5) MW: 555.7 H-Tyr-Gly-Gly-Phe-Leu-OH Hughes, J. et al. (1975) Nature 258, 577. 25mg 100mg SBP0109 - [Leu5]-Enkephalin Amide MW: 554.7 H-Tyr-Gly-Gly-Phe-Leu-NH2 25mg 100mg SBP0110 - [Met5]-Enkephalin Amide MW: 572.8 H-Tyr-Gly-Gly-Phe-Met-NH2 Chang, J.K. et al. (1976) Life Science 18, 1473. 25mg 100mg SBP0111 - [D-Ala2,Leu5,Arg6]-Enkephalin Dalargin MW: 725.9 H-Tyr-D-Ala-Gly-Phe-Leu-Arg-OH Ilylnsky, O.B. et al. (1990) Ann. N.Y. Acad. Sci. 594, 461. 10mg 25mg Enterostatins SBP0112 - Enterostatin, human MW: 496.6 H-Ala-Pro-Gly-Pro-Arg-OH This pentapeptide is released from the N-terminal of pancreatic colipase. It is reported to act as a systemic satiety factor governing fat intake. Erlanson-Albertsson C. & Larsson A (1988) Regul. Peptides 22, 325; Erlanson-Albertsson C. & Larsson A (1988) Biochimie 70, 1245; Erlanson-Albertsson C. (1991) Physiol. Behav. 49, 1191. 5mg 25mg Exendins and Fragments SBP0113 - Exendin 3 MW: 4203.1 H-His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 Exendin-3 is a 39-mer peptide, originally isolated from the venom of the Guatemalan beaded lizard (Heloderma horridum). The peptide binds to the GLP-1 receptor and acts as a potent GLP-1 (7-36) amide agonist. Eng et al. (1992) JBC 267, 7402 500µg 1mg SBP0114 - Exendin 4 MW: 4187.1 H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 Exendin-4 is a 39-mer peptide, originally isolated from the venom of gila monster (Heloderma suspectum). The peptide binds to the GLP-1 receptor and acts as a potent GLP-1 (7-36) amide agonist. Differs from exendin-3 by only 2 N-terminal amino acid substitutions. Fehmann et al. (1994) Peptides 15, 453 500µg 1mg SBP0115 - Exendin 4 (3-39) MW: 3992.8 H-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 Exendin-4 (3-39) is a potent GLP-1 (7-36) amide receptor antagonist. Montrose-Rafizadch et al. (1996) Regulatory Peptides 64, 131 500µg 1mg SBP0116 - Exendin 3 (9-39) MW: 3370.2 H-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 Exendin (9-39) binds with high affinity to the glucagon-like peptide-1 (7-36) amide receptor acting as a potent GLP-1 antagonist. Eng J. et al. (1992) J. Biol. Chem. 267, 7402; Raufman, J.-P. et al. (1992) J. Biol. Chem. 267, 21432; Fehmann, H.C. et al. (1994) Peptides 15, 453. 500µg 1mg Fibrinogen Fragments and Related Peptides SBP0117 - Fibrinopeptide A, human MW: 1536.8 H-Ala-Asp-Ser-Gly-Glu-Gly-Asp-Phe-Leu-Ala-Glu-Gly-Gly-Gly-Val-Arg-OH 1mg 5mg SBP0118 - GPRP Fibrin Antipolymerant MW: 425.5 H-Gly-Pro-Arg-Pro-OH Plow E.F. et al. (1987) Biochem. Pharmacol. 36, 4035 This peptide is supplied as the acetate salt. 25mg 100mg SBP0119 - RGDS (Fibronectin Attachment Peptide) MW: 433.5 H-Arg-Gly-Asp-Ser-OH Pierschbacher, M.D. et al. (1984) Nature 309, 30; Gartner, T.K. et al. (1985) J. Biol. Chem. 260, 11891; Ginsberg, M. et al. (1985) J. Biol. Chem. 260, 3931; Haverstick et al. (1985) Blood 66, 946; Thomas D.D. et al. (1985) J. Exp. Med. 162, 1715. 10mg 25mg SBP0120 - GRGDS (Fibronectin Attachment Peptide) MW: 490.5 H-Gly-Arg-Gly-Asp-Ser-OH Akiyama, S.K. & Yamada, K.M. (1985) J. Biol. Chem. 260, 10402; Humphries, M.J. et al. (1986) Science 233, 467 10mg 25mg SBP0121 - GRGDSPK (Fibronectin Attachment Peptide) MW: 715.9 H-Gly-Arg-Gly-Asp-Ser-Pro-Lys-OH Pytela, R. et al. (1986) Science 231, 1559. 1mg 5mg SBP0122 - Tyr-Amyloid P Component (27-38) Amide [Tyr0]-Amyloid P Component Dodecapeptide MW: 1657.1 H-Tyr-Glu-Lys-Pro-Leu-Gln-Asn-Phe-Thr-Leu-Cys-Phe-Arg-NH2 Dhawan, S,. et al. (1990) Biochem. Biophys. Res. Commun. 171, 1284 1mg 5mg SBP0123 - Tyr-Amyloid P Component (33-38) Amide [Tyr0]-Amyloid P Component Hexapeptide MW: 948.2 H-Tyr-Phe-Thr-Leu-Cys-Phe-Arg-NH2 Dhawan, S,. et al. (1990) Biochem. Biophys. Res. Commun. 171, 1284 1mg 5mg Galanin and Related Peptides SBP0124 - Galanin, human MW: 3157.5 H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-His-Ala-Val-Gly-Asn-His-Arg-Ser-Phe-Ser-Asp-Lys-Asn-Gly-Leu-Thr-Ser-OH Bersani, M. et al. (1991) FEBS Letters 283, 189; Evans, H.F. et al. 81991) Endocrinology 129, 1682, Schmidt W.E. et al. (1991) Proc. Soc. Natl. Acad. Sci. USA 88, 11435. 500µg 1mg SBP0125 - Galanin, porcine MW: 3211 H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-His-Ala-Ile-Asp-Asn-His-Arg-Ser-Phe-His-Asp-Lys-Tyr-Gly-Leu-Ala-NH2 Tatemoto, K. et al. (1983) FEBS Letters 164, 124. 500µg 1mg SBP0126 - Galanin, rat MW: 3164.3 H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-His-Ala-Ile-Asp-Asn-His-Arg-Ser-Phe-Ser-Asp-Lys-His-Gly-Leu-Thr-NH2 Kaplan, L.M. et al. (1988) Proc. Soc. Natl. Acad. Sci. USA 85, 1065. 500µg 1mg SBP0127 - Galanin (1-13) - Pro2-(Ala-Leu)2-Ala Amide M40 MW: 1981.6 H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-Pro-Pro-Ala-Leu-Ala-Leu-Ala-NH2 Leibowitz, S.F. & Kim. T. (1992) Brain Res. 599, 148; Crawley, J.N. et al. (1993) Brain Res. 600, 268. 500µg 1mg SBP0128 - Galanin (1-13) - Bradykinin (2-9) Amide MW: 2233.9 H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-NH2 Oegren, O. et al. (1992) Neuroscience 51, 1: Bartfai, T. et al. (1992) TIPS 13, 312. 500µg 1mg SBP0129 - Galanin (1-13) - Spantide-NH2 C7 MW: 2828.6 H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-D-Arg-Pro-Lys-Pro-Gln-Gln-D-Trp-Phe-D-Trp-Leu-Leu-NH2 Crawley, J.N. et al. (1993) Brain Res. 600, 268. 500µg 1mg SBP0130 - Galanin (1-13) - Substance P (5-11) Amide Galantide MW: 2199.8 H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 Bartfai, T. et al. (1991) Proc. Soc. Natl. Acad. Sci. USA 88, 10961; Lindskog, S. et al. (1992) Eur. J. Pharmacol. 210, 183; Langel, U. et al. (1992) Int. J. Peptide Protein Res. 39, 516; Bartfei, T. et al. (1992) TIPS 13, 312. 500µg 1mg Gastric Inhibitory Polypeptide (GIP) and Related Peptides SBP0131 - Gastric Inhibitory Polypeptide (GIP), human MW: 4984.2 H-Tyr-Ala-Glu-Gly-Thr-Phe-Ile-Ser-Asp-Tyr-Ser-Ile-Ala-Met-Asp-Lys-Ile-His-Gln-Gln-Asp-Phe-Val-Asn-Trp-Leu-Leu-Ala-Gln-Lys-Gly-Lys-Lys-Asn-Asp-Trp-Lys-His-Asn-Ile-Thr-Gln-OH Moody, A. et al. (1981) FEBS Letters 123, 205 500µg 1mg Gastrin and Related Peptides SBP0132 - Gastrin I, human MW: 2098.5 pGlu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 Bentley, P.H. et al. (1966) Nature 209, 583; Walsh, J.H. et al. (1977) Fed. Proc. 36, 1719. 1mg 5mg SBP0133 - Gastrin I, rat MW: 2126.2 pGlu-Arg-Pro-Pro-Met-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 Reeves, J.R. et al. (1981) Peptides 2, 45; Schaffer et al. (1982) Peptides 3, 693. 1mg 5mg SBP0134 - [Leu15]-Gastrin (5-17) [Leu11]-Minigastrin MW: 1628.8 H-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Leu-Asp-Phe-NH2 1mg 5mg SBP0135 - Pentagastrin MW: 767.9 Boc-ß-Ala-Trp-Met-Asp-Phe-NH2 25mg 100mg Gastrin Releasing Peptide (GRP) and Related Peptides SBP0136 - Gastrin Releasing Peptide (GRP), human MW: 2859.4 H-Val-Pro-Leu-Pro-Ala-Gly-Gly-Gly-Thr-Val-Leu-Thr-Lys-Met-Tyr-Pro-Arg-Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2 Spindel, E.R. et al. (1984) Proc. Soc. Natl. Acad. Sci. USA 81, 5699; Sunday, M.E. et al. (1988) Lab. Invest. 54, 5; Olsen, L. et al. (1992) Endocrinology 130, 2710; Steel, J.H. et al. (1992) Endocrinology 130, 2587. 500µg 1mg Ghrelins and Related Peptides SBP0137 - Ghrelin, human MW: 3370.9 H-Gly-Ser-Ser(Octanoyl)-Phe-Leu-Ser-Pro-Glu-His-Gln-Arg-Val-Gln-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg-OH Endogenous agonist peptide for the orphan growth hormone secretagogue (GHS) receptor. Produced mainly in the stomach, it stimulates release of growth hormone fro the pituitary gland in vitro and in vivo, and regulates feeding, growth and energy production. 1mg 5mg SBP0138 - Ghrelin, rat MW: 3314.83 H-Gly-Ser-Ser(Octanoyl)-Phe-Leu-Ser-Pro-Glu-His-Gln-Lys-Ala-Gln-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg-OH Endogenous agonist peptide for the orphan growth hormone secretagogue (GHS) receptor. Produced mainly in the stomach, it stimulates release of growth hormone fro the pituitary gland in vitro and in vivo, and regulates feeding, growth and energy production. 1mg 5mg SBP0139 - des-Gln14-Ghrelin, rat MW: 3186.70 H-Gly-Ser-Ser(Octanoyl)-Phe-Leu-Ser-Pro-Glu-His-Gln-Lys-Ala-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg-OH Endogenous agonist peptide for the orphan growth hormone secretagogue (GHS) receptor. Produced producd by alternative splicing of the rat ghrelin gene. Potently induces Ca2+ release in cells expressing GHS receptors (EC50 = 2.4nM) and stimulates GH release in vivo. 1mg 5mg SBP0140 - Biotinyl-Ghrelin, human MW: 3592.9 Biotin-Gly-Ser-Ser(Octanoyl)-Phe-Leu-Ser-Pro-Glu-His-Gln-Arg-Val-Gln-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg-OH Endogenous agonist peptide for the orphan growth hormone secretagogue (GHS) receptor. Labelled with biotin at the N-terminus. 1mg 5mg SBP0141 - Biotinyl-Ghrelin, rat MW: 3536.83 Biotin-Gly-Ser-Ser(Octanoyl)-Phe-Leu-Ser-Pro-Glu-His-Gln-Lys-Ala-Gln-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg-OH Endogenous agonist peptide for the orphan growth hormone secretagogue (GHS) receptor. Labelled with biotin at the N-terminus. 1mg 5mg SBP0142 - Biotinyl-des-Gln14-Ghrelin, rat MW: 3408.70 Biotin-Gly-Ser-Ser(Octanoyl)-Phe-Leu-Ser-Pro-Glu-His-Gln-Lys-Ala-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg-OH Endogenous agonist peptide for the orphan growth hormone secretagogue (GHS) receptor. Labelled with biotin at the N-terminus. 1mg 5mg SBP0143 - Non-octanoyl-Ghrelin, human MW: 3244.74 H-Gly-Ser-Ser-Phe-Leu-Ser-Pro-Glu-His-Gln-Arg-Val-Gln-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg-OH Non-acylated control. 1mg 5mg SBP0144 - Non-octanoyl-Ghrelin, rat MW: 3188.67 H-Gly-Ser-Ser-Phe-Leu-Ser-Pro-Glu-His-Gln-Lys-Ala-Gln-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg-OH Non-acylated control. 1mg 5mg SBP0145 - Non-Octanoyl-des-Gln14-Ghrelin, rat MW: 3060.54 H-Gly-Ser-Ser-Phe-Leu-Ser-Pro-Glu-His-Gln-Lys-Ala-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg-OH Non-acylated control. 1mg 5mg SBP0146 - Hexarelin GHRP6 MW: 886.06 H-His-2Me-D-Trp-Ala-Trp-D-Phe-Lys-NH2 500µg 1mg Glucagon and Related Peptides SBP0147 - Glucagon (1-29), bovine, human, porcine MW: 3482.6 H-His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-OH 500µg 1mg SBP0148 - Glucagon (19-29), bovine, human, porcine MW: 1352.7 H-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-OH Mallat, A. et al. (1987) Nature 325, 620. 1mg 5mg SBP0149 - [Des-His1,Des-Phe6,Glu7]-Glucagon (1-29), bovine, human, porcine MW: 3212.7 H-Ser-Gln-Gly-Thr-Thr-Ser-Glu-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-OH A glucagon receptor antagonist. It binds to the glucagon receptor, but fails to activate the adenylate cyclase signal transduction system. Azizeh, B.Y. et al. (1997) J. Med. Chem. 40, 2555 500µg 1mg Glucagon-Like Peptide (GLP) and Related Peptides SBP0150 - Glucagon-Like Peptide I (7-36) Amide, human Preproglucagon (78-107) Amide, human MW: 3297.5 H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH2 Bell, G. et al. 81983) Nature 304, 368. 500µg 1mg SBP0151 - Glucagon-like Peptide 2, human GLP-2 MW: 3766.7 H-His-Ala-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp-OH Primary cleavage product of proglucagon in intestinal L cells. Recent studies indicate that GLP-2 has trophic action on the jejenum, ileum and colon. It , or analogues, should be potential candidates for treating short bowel syndrome. Orskov C. et al. (1986) Endocrinology 119, 1467; Buhl T. et al. (1988) J. Biol. Chem. 263, 8621; Orskov C. et al. (1989) FEBS Letters 247, 193; Drucker D.J. et al. (1996) Proc. Natl. Acad. Sci. USA 93, 7911; Tsai C.H. et al. (1997) Am. J. Physiol. 272, G662. 500µg 1mg Growth Factors and Related Peptides SBP0152 - VEGF Exon 6 Peptide MW: 1748.4 H-Gly-Lys-Gly-Gln-Lys-Arg-Lys-Arg-Lys-Lys-Ser-Arg-Tyr-Lys-OH 1mg 5mg Growth Hormone Releasing Factors (GRF, GHRH), and Related Peptides SBP0153 - Growth Hormone Releasing Factor (1-44), bovine MW: 5108.6 H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Asn-Arg-Gln-Gln-Gly-Glu-Arg-Asn-Gln-Glu-Gln-Gly-Ala-Lys-Val-Arg-Leu-NH2 Esch, F. et al. (1983) Biochem. Biophys. Res. Commun. 17, 772. 500µg 1mg SBP0154 - Growth Hormone Releasing Factor (1-44), human MW: 5040.4 H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2 Guillemin, R. et al. (1982) Science 218, 585. 500µg 1mg SBP0155 - Growth Hormone Releasing Factor (1-29) Amide, human MW: 3358.4 H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2 Zarandi, M. et al. (1990) Int. J. Peptide Protein Res. 36, 499; Vance, M.L. (1990) Clin. Chem. 36, 415; Zarandi, M. et al. (1992) Int. J. Peptide Protein Res. 39, 211. 500µg 1mg SBP0156 - [D-Ala2]-GRF (1-29) amide, human MW: 3358.4 H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2 In terms of GH secretion from the pituitary, this GHRH analogue is about 50 times more potent than GHRH (1-29) itself. Lance V.A. et al. (1984) Biochem. Biophys. Res. Commun. 119, 265; Robberecht P. et al. (1986) Peptides 7 (Suppl. 1), 53; Campbell et al. (1991) Peptides 12, 569. 500µg 1mg SBP0157 - [D-Tle2]-GRF (1-29) amide, human MW: 3400 H-Tyr-D-Tle-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2 Lidicky J. et al. (1992) Biopharm 2, 147. 500µg 1mg SBP0158 - [D-Tle2,Nle26]-GRF (1-29) amide, human MW: 3382 H-Tyr-D-Tle-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Nle-Ser-Arg-NH2 500µg 1mg SBP0159 - [Nle26]-Growth Hormone Releasing Factor (1-29) Amide, human MW: 3340.4 H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Nle-Ser-Arg-NH2 Rivier, J. et al. (1988) Ann. N.Y. Acad. Sci. 527, 44. 500µg 1mg SBP0160 - Growth Hormone Releasing Factor (1-44), ovine MW: 5122.6 H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Ile-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Asn-Arg-Gln-Gln-Gly-Glu-Arg-Asn-Gln-Glu-Gln-Gly-Ala-Lys-Val-Arg-Leu-NH2 Brazeau, P. et al. (1984) Biochem. Biophys. Res. Commun. 125, 606. 500µg 1mg HPV Peptides SBP0161 - HPV-16 E7 MW: 1210.4 H-Tyr-Met-Leu-Asp-Leu-Gln-Pro-Glu-Glu-Thr-Thr-OH Peptide from HPV used in immunoassay. 1mg 5mg HIV Related Peptides SBP0162 - HIV Peptide gp120 (254-274) MW: 2208.9 H-Cys-Thr-His-Gly-Ile-Arg-Pro-Val-Val-Ser-Thr-Gln-Leu-Leu-Leu-Asn-Gly-Ser-Leu-Ala-Glu-OH Ho, D.D. et al. (1988) Science 239, 1021. 500µg 1mg SBP0163 - HIV Protease Substrate III MW: 1314.7 H-His-Lys-Ala-Arg-Val-Leu-p-nitro-Phe-Glu-Ala-Nle-Ser-NH2 Pennington, M.W. et al. (1990) Proc. 21st Europ. Peptide Symp. p. 787, eds.: Giralt, E. & Andreu, D. (Escom, Leiden). 1mg 5mg Interleukin Fragments and Related Peptides SBP0164 - Interleukin-6 (88-121), human MW: 4023.8 H-Ile-Ile-Thr-Gly-Leu-Leu-Glu-Phe-Glu-Val-Tyr-Leu-Glu-Tyr-Leu-Gln-Asn-Arg-Phe-Glu-Ser-Ser-Glu-Glu-Gln-Ala-Arg-Ala-Val-Gln-Met-Ser-Thr-Lys-OH A competitive inhibitor of IL-6 binding Ekida, T et al. (1992) Biochem. Biophys. Res. Commun. 188, 912. 500µg 1mg Ion Channel Modulators SBP0165 - ß-Pompilidotoxin MW: 1557.90 H-Arg-Ile-Lys-Ile-Gly-Leu-Phe-Asp-Gln-Leu-Ser-Arg-Leu-NH2 Slows neuronal Na+ channel inactivation. Konno et al (1998) Biochem.Biophys.Res.Comm. 260 612. 500µg 1mg SBP0166 - Charybdotoxin MW: 4295.95 pGlu-Phe-Thr-Asn-Val-Ser-Cys-Thr-Thr-Ser-Lys-Glu-Cys-Trp-Ser-Val-Cys-Gln-Arg-Leu-His-Asn-Thr-Ser-Arg-Gly-Lys-Cys-Met-Asn-Lys-Lys-Cys-Arg-Cys-Tyr-Ser-OH (Cys7-28, Cys13-33, Cys17-35, tricyclic) Specific inhibitor of the high conductance Ca2+-activated K+ channel.. Miller et al (1995) Nature 313 316. 0.1 mg 500µg SBP0167 - Iberiotoxin MW: 4230.00 pGlu-Phe-Thr-Asp-Val-Asp-Cys-Ser-Val-Ser-Lys-Glu-Cys-Trp-Ser-Val-Cys-Lys-Asp-Leu-Phe-Gly-Val-Asp-Arg-Gly-Lys-Cys-Met-Gly-Lys-Lys-Cys-Arg-Cys-Tyr-Gln-OH (Cys7-28, Cys13-33, Cys17-35, tricyclic) Specific inhibitor of the high conductance Ca2+-activated K+ channel.. Galvez et al (1990) J.Med.Chem 37 636. 0.1 mg 500µg Leptin Fragments and Related Peptides SBP0168 - Leptin (22-56), human MW: 3950.6 H-Val-Pro-Ile-Gln-Lys-Val-Gln-Asp-Arg-Thr-Lys-Thr-Leu-Ile-Lys-Thr-Ile-Val-Thr-Arg-Ile-Asn-Asp-Ile-Ser-His-Thr-Gln-Ser-Val-Ser-Ser-Lys-Gln-Lys-OH This leptin fragment has been shown to reduce food intake in rats. Samson W.K. et al. (1996) Endocrinology 137, 5182. 500µg 1mg Luteinizing Hormone Releasing Hormone (LHRH) and Related Peptides SBP0169 - LHRH, human Gonadorelin MW: 1182.4 pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 Rivier, J. & Vale, W.W. (1978) Life Science 23, 869; Tilemans, D. et al. (1992) Endocrinology 130, 887. 10mg 25mg SBP0170 - [D-Ala6]-LHRH MW: 1196.5 pGlu-His-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 Monahan, M.W. et al. (1973) Biochem. 12, 4616. 5mg 25mg SBP0171 - [D-Lys6]-LHRH MW: 1253.6 pGlu-His-Trp-Ser-Tyr-D-Lys-Leu-Arg-Pro-Gly-NH2 5mg 25mg SBP0172 - [D-Trp6]-LHRH Triptorelin MW: 1311.6 pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2 Schally, A.V. et al. (1985) Proc. Soc. Natl. Acad. Sci. USA 82, 2498. 5mg 25mg SBP0173 - [D-Ser(tBu)6,Aza-Gly10]-LHRH Goserelin MW: 1269 pGlu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-Aza-Gly-NH2 500µg 1mg SBP0174 - [D-Tle6,Pro-NHEt9]-LHRH Lecirelin MW: 1209.4 pGlu-His-Trp-Ser-Tyr-Tle-Leu-Arg-Pro-NHEt This position 6 D-tert-leucine substituted LHRH analogue was compared with [D-Ala6, Pro-NHEt9]-LHRH and found to significantly more active in sustaining enhanced LH and FSH in heifers. Flegel (1983) Peptides 1982, Walter de Gruyter & Co., Berlin, New York, pp 551. 5mg 25mg SBP0175 - [Des-Gly10,D-Ala6,Pro-NHEt9]-LHRH MW: 1167.4 pGlu-His-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-NHEt Levitan, D. et al. (1977) Endocrinology 100, 918; Corbin, A. et al. (1978) Infect. Fertil. 23, 81; Coy, D.H. & Schally, A.V. (1978) Ann. Clin. Res. 10, 139. 5mg 25mg SBP0176 - [Des-Gly10, D-Leu6, Pro-NHEt9]-LHRH Leuprolide MW: 1209.5 pGlu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt Coy, D.H. & Schally, A.V. (1978) Ann. Clin. Res. 10, 139; Dutta, A.S. (1988) Drugs of the Future 13, 43. 5mg 25mg SBP0177 - [Des-Gly10,Pro-NHEt9]-LHRH MW: 1153.4 pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-NHEt Fujino, M. et al. (1972) Biochem. Biophys. Res. Commun. 49, 863; Okada, J. & Kondo, S. (1985) Chem. Pharm. Bull. 33, 4464. 5mg 25mg SBP0178 - [Des-Gly10,D-Trp6,Pro-NHEt9]-LHRH Deslorelin MW: 1282.6 pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-NHEt Coy, D.V. & Schally, A.V. (1978) Ann. Clin. Res. 10, 139; Foster, C.M. et al. (1984) J. Clin. Endocrinol. Metab. 59, 801; Klibanski, A. et al. (1989) J. Clin. Endocrinol. Metab. 68, 81. 5mg 25mg SBP0179 - [Des-Gly10,D-Ser(tBu)6,Pro-NHEt9]-LHRH Buserelin MW: 1239.5 p-Glu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-NHEt 500µg 1mg SBP0180 - [Des-Gly10,D-His2,D-Ser(tBu)6,Pro-NHEt9]-LHRH [D-His2]-Buserelin MW: 1239.5 p-Glu-D-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-NHEt Mandatory European Pharmacopoeia reference standard for assay of buserelin 500µg 1mg SBP0181 - LHRH-III, lamprey MW: 1259.5 pGlu-His-Trp-Ser-His-Asp-Trp-Lys-Pro-Gly-NH2 Selective FSH-releasing activity has been demonstrated on a number of occasions, but until now the molecule responsible for this action has not been isolated. In view of the FSH-releasing action of LHRH, this peptide has often been postulated to be responsible for both FSH and LH secretion from the pituitary. Recent in vitro and in vivo experiments with rats have shown that lamprey LHRH-III selectively stimulates the release of FSH without affecting LH. It is postulated that this sequence may represent the long sought after endogenous FSH-releasing factor. Sower, S.A. et al. (1993) Endocrinology 132, 1125; Yu, W.H. et al. (1997) Proc. Soc. Natl. Acad. Sci. USA 94, 9499. 5mg 25mg SBP0182 - LHRH (1-5)-OMe MW: 716.9 pGlu-His-Trp-Ser-Tyr(Me)-OH 5mg 25mg Matrix Metalloproteinase (MMP) Substrates SBP0183 - Matrix Metalloprotease 2 and 9 Substrate DNP-PLGMWSR MW: 1012.1 DNP-Pro-Leu-Gly-Met-Trp-Ser-Arg-OH Netzel-Arnett S. et al. (1991) Anal Biochem. 195, 86. 5mg 25mg Melanocyte Stimulating Hormones (MSH) and Related Peptides SBP0184 - α-MSH Acetyl-ACTH (1-13) Amide MW: 1665.1 Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 Harris, J.I. et al. (1957) Nature 179, 1346; Blake, J. & Li. C.H. (1971) Int. J. Protein Res. 111, 185. 5mg 25mg SBP0185 - [Nle4]-α-MSH MW: 1647 Ac-Ser-Tyr-Ser-Nle-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 1mg 5mg SBP0186 - [Nle4,D-Phe7]-α-MSH MW: 1647 Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 Sawyer, T. et al. (1980) Proc. Soc. Natl. Acad. Sci. USA 77, 5754. 1mg 5mg SBP0187 - [Des-Acetyl]-α -MSH ACTH (1-13) Amide MW: 1623.1 H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 1mg 5mg SBP0188 - [N-Acetyl-Cys4,D-Phe7,Cys10]-α-MSH (4-13), cyclic MW: 1343.7 Ac-Cys-Glu-His-D-Phe-Arg-Trp-Cys-Lys-Pro-Val-NH2 (Cys4-10, cyclic) Cody, W.L. et al. (1985) J. Med. Chem. 28, 583. 1mg 5mg SBP0189 - [N-Acetyl-Nle4,Asp5,D-2'-Nal7,Lys10]-α -MSH (4-10) Amide (Asp5-Lys10, cyclic lactam) SHU-9119 MW: 1074.5 Ac-Nle-Asp-His-D-2`-Nal-Arg-Trp-Lys-NH2 (Asp5-Lys10, cyclic lactam) Fan et al.(1997) Nature 385, 165 - 168 1mg 5mg SBP0190 - [N-Acetyl-Nle4,Asp5, D-Phe7,Lys10]-α -MSH (4-10) Amide (Asp5-Lys10, cyclic lactam) MTII MW: 1024.3 Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2 (Asp5-Lys10, cyclic lactam) Fan et al.(1997) Nature 385, 165 - 168 1mg 5mg SBP0191 - [N-Acetyl-Nle4,Gln5,D-Phe7,D-Trp9]-α -MSH (4-10) Amide HP-228 MW: 984.2 Ac-Nle-Gln-His-D-Phe-Arg-D-Trp-Gly-NH2 Alpha-MSH is known to act as a protective agent against LPS-induced endotoxic shock. HP-228, a structurally related heptapeptide, is a significantly more effective in vivo protective agent. It prevents the induction of nitric oxide synthase activity and endotoxic shock by LPS in rats in vivo, but not in vitro. Thus, its action appears to be indirect, involving a metabolite or additional mediator. Abou-Mohamed et al. (1995) J. Pharmacol. Exptl. Therap. 275, 584 1mg 5mg SBP0192 - [Met5,Pro6,D-Phe7,D-Trp9,Phe10]-α -MSH (5-13) MW: 1206.5 H-Met-Pro-D-Phe-Arg-D-Trp-Phe-Lys-Pro-Val-NH2 Jayawickreme, C.K. et al. (9954) J. Biol. Chem. 269, 29846. 1mg 5mg SBP0193 - ß-MSH, human MW: 2661.3 H-Ala-Glu-Lys-Lys-Asp-Glu-Gly-Pro-Tyr-Arg-Met-Glu-His-Phe-Arg-Trp-Gly-Ser-Pro-Pro-Lys-Asp-OH 1mg 5mg SBP0194 - γ1-MSH MW: 1512.9 H-Tyr-Val-Met-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-NH2 Nakanishi, S. et al. (1979) Nature 278, 423; Ling, N. et al. (1979) Life Science 25, 1773. 1mg 5mg SBP0195 - γ2-MSH MW: 1571.1 H-Tyr-Val-Met-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-Gly-OH Nakanishi, S. et al. (1979) Nature 278, 423; Ling, N. et al. (1979) Life Science 25, 1773. 1mg 5mg Motilin and Related Peptides SBP0196 - Motilin, human, porcine MW: 2699.2 H-Phe-Val-Pro-Ile-Phe-Thr-Tyr-Gly-Glu-Leu-Gln-Arg-Met-Gln-Glu-Lys-Glu-Arg-Asn-Lys-Gly-Gln-OH Motilin stimulates gastric motor activity. De Clercq, P. et al. (1995) Regul. Peptides 55, 79 500µg 1mg SBP0197 - [Leu13]-Motilin, human, porcine MW: 2681.2 H-Phe-Val-Pro-Ile-Phe-Thr-Tyr-Gly-Glu-Leu-Gln-Arg-Leu-Gln-Glu-Lys-Glu-Arg-Asn-Lys-Gly-Gln-OH This motilin analogue stimulates gastric motor activity. Miyashita E. et al. (1988) Biotechnology Letters 10, 763. 500µg 1mg Myelin Proteins SBP0198 - Myelin Oligodendrocyte Glycoprotein (1-22) MOG 1-22 MW: 2458.9 H-Gly-Gln-Phe-Arg-Val-Ile-Gly-Pro-Arg-His-Pro-Ile-Arg-Ala-Leu-Val-Gly-Asp-Glu-Val-Glu-Leu-OH Multiple sclerosis candidate autoantigen fragment. 1mg 5mg SBP0199 - Myelin Oligodendrocyte Glycoprotein (34-56) MOG 34-56 MW: 2764.2 H-Gly-Met-Glu-Val-Gly-Trp-Tyr-Arg-Pro-Pro-Phe-Ser-Arg-Val-Val-His-Leu-Tyr-Arg-Asn-Gly-Lys-Asp-OH Multiple sclerosis candidate autoantigen fragment. 1mg 5mg SBP0200 - Myelin Oligodendrocyte Glycoprotein (64-86) MOG 64-86 MW: 2674.1 H-Glu-Tyr-Arg-Gly-Arg-Thr-Glu-Leu-Leu-Lys-Asp-Ala-Ile-Gly-Glu-Gly-Lys-Val-Thr-Leu-Arg-Ile-Arg-OH Multiple sclerosis candidate autoantigen fragment. 1mg 5mg SBP0201 - Myelin Oligodendrocyte Glycoprotein (74-96) MOG 74-96 MW: 2536.9 H-Asp-Ala-Ile-Gly-Glu-Gly-Lys-Val-Thr-Leu-Arg-Ile-Arg-Asn-Val-Arg-Phe-Ser-Asp-Glu-Gly-Gly-Phe-OH Multiple sclerosis candidate autoantigen fragment. 1mg 5mg SBP0202 - Proteolipid Protein (41-58) PLP 41-58 MW: 2228.4 H-Gly-Thr-Glu-Lys-Leu-Ile-Glu-Thr-Tyr-Phe-Ser-Lys-Asn-Tyr-Gln-Asp-Tyr-Glu-OH Multiple sclerosis candidate autoantigen fragment. 1mg 5mg SBP0203 - Proteolipid Protein (184-199) PLP 184-199 MW: 1593.8 H-Gln-Ser-Ile-Ala-Phe-Pro-Ser-Lys-Thr-Ser-Ala-Ser-Ile-Gly-Ser-Leu-OH Multiple sclerosis candidate autoantigen fragment. 1mg 5mg SBP0204 - Proteolipid Protein (190-209) PLP 190-209 MW: 2029.4 H-Ser-Lys-Thr-Ser-Ala-Ser-Ile-Gly-Ser-Leu-Cys-Ala-Asp-Ala-Arg-Met-Tyr-Gly-Val-Leu-OH Multiple sclerosis candidate autoantigen fragment. 1mg 5mg SBP0205 - Myelin Basic Protein (84-102) MBP 84-102 MW: 2147.5 H-Asn-Pro-Val-Val-His-Phe-Phe-Lys-Asn-Ile-Val-Thr-Pro-Arg-Thr-Pro-Pro-Pro-Ser-OH Multiple sclerosis candidate autoantigen fragment. 1mg 5mg SBP0206 - Myelin Basic Protein (143-168) MBP 143-168 MW: 2636.0 H-Gly-Val-Asp-Ala-Gln-Gly-Thr-Leu-Ser-Lys-Ile-Phe-Lys-Leu-Gly-Gly-Arg-Asp-Ser-Arg-Ser-Gly-Ser-Pro-Met-Ala-OH Multiple sclerosis candidate autoantigen fragment. 1mg 5mg Neurokinins, Neuromedins, Other Tachykinins and Related Peptides SBP0207 - [ß-Ala8]-Neurokinin A (4-10) MW: 780.9 H-Asp-Ser-Phe-Val-ß-Ala-Leu-Met-NH2 Evangelista, S. et al. (1990) Peptides 11, 293. 1mg 5mg SBP0208 - Neuromedin U8 MW: 1111.4 H-Tyr-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH2 1mg 5mg Neuropeptide AF and FF, HLWAR77 receptor agonists SBP0209 - Neuropeptide AF MW: 1978.19 H-Ala-Gly-Glu-Gly-Leu-Asn-Ser-Gln-Phe-Trp-Ser-Leu-Ala-Ala-Pro-Gln-Arg-Phe-NH2 Anti-opioid peptide. Agonist or orphan G-coupled receptor HLWAR77. 1 mg 5 mg SBP0210 - Neuropeptide SF (Neuropeptide FF-amide) MW: 1367.57 H-Ser-Gln-Ala-Phe-Leu-Phe-Gln-Pro-Gln-Arg-Phe-NH2 Anti-opioid peptide. Agonist or orphan G-coupled receptor HLWAR77. 1mg 5mg Neuropeptide Y (NPY) and Related Peptides SBP0211 - Neuropeptide Y, human, rat MW: 4272.2 H-Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2 Minth, C. et al. (1984) Proc. Soc. Natl. Acad. Sci. USA 81, 4577; Millar, B.C. et al. (1991) Am. J. Physiol. 261, H1727. 500µg 1mg SBP0212 - Biotinyl-Neuropeptide Y, human, rat MW: 4498.5 Biotinyl-Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2 500µg 1mg SBP0213 - [Leu31,Pro34]-Neuropeptide Y, human, rat MW: 4241.2 H-Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Leu-Thr-Arg-Pro-Arg-Tyr-NH2 Fuhlendorf, J. et al. (1980) Proc. Soc. Natl. Acad. Sci. USA 87, 182. 500µg 1mg SBP0214 - [D-Trp32]-Neuropeptide Y, human, rat MW: 4357.3 H-Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-D-Trp-Arg-Gln-Arg-Tyr-NH2 Balasubramaniam, A. et al. (1994) J. Med. Chem. 37, 811. 500µg 1mg SBP0215 - Neuropeptide Y (1-24) Amide, human MW: 2657.2 H-Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-NH2 Martel, J.C. et al. (1990) Mol. Pharmacol. 38, 494. 500µg 1mg SBP0216 - Neuropeptide Y (2-36), human, rat MW: 4109 H-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2 500µg 1mg SBP0217 - Neuropeptide Y (3-36), human, rat MW: 4011.9 H-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2 Grandt, D. et al. (1996) Regul. Peptides 67, 33. 500µg 1mg SBP0218 - Neuropeptide Y (13-36), human, rat MW: 3000.8 H-Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2 500µg 1mg SBP0219 - [Leu31,Pro34]-Neuropeptide Y (13-36), human, rat MW: 2969.8 H-Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Leu-Thr-Arg-Pro-Arg-Tyr-NH2 500µg 1mg SBP0220 - Neuropeptide Y, porcine MW: 4254.2 H-Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Leu-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2 Tatemoto, K. et al. (1982) Proc. Soc. Natl. Acad. Sci USA 79, 5485. 500µg 1mg SBP0221 - Biotinyl-Neuropeptide Y, porcine MW: 4480.5 Biotinyl-Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Leu-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2 500µg 1mg SBP0222 - [Leu31,Pro34]-Neuropeptide Y, porcine MW: 4223.2 H-Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Leu-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Leu-Thr-Arg-Pro-Arg-Tyr-NH2 Fuhlendorf, J. et al. (1990) Proc. Soc. Natl. Acad. Sci. 87, 182. 500µg 1mg SBP0223 - [Pro34]-Neuropeptide Y, porcine MW: 4223.2 H-Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Leu-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Pro-Arg-Tyr-NH2 Potter, E.K. et al. (1991) Eur. J. Pharmacol. 193, 15. 500µg 1mg SBP0224 - [D-Trp32]-Neuropeptide Y, porcine MW: 4339.3 H-Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Leu-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-D-Trp-Arg-Gln-Arg-Tyr-NH2 Balasubramaniam, A. et al. (1994) J. Med. Chem. 37, 811. 500µg 1mg SBP0225 - Neuropeptide Y (2-36), porcine MW: 4091 H-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Leu-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2 Taoudi Benchekroun, M. et al. (1993) Br. J. Pharmacol. 109, 902. 500µg 1mg SBP0226 - Neuropeptide Y (3-36), porcine MW: 3993.9 H-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Leu-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2 Grandt, D. et al. (1996) Regul. Peptides 40, 161. 500µg 1mg SBP0227 - Neuropeptide Y (13-36), porcine MW: 2982.7 H-Pro-Ala-Glu-Asp-Leu-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2 Walker, M.W. & Millar, R.J. (1988) Mol. Pharmacol. 34, 779. 500µg 1mg SBP0228 - [Leu31,Pro34]-Neuropeptide Y (13-36), porcine MW: 2951.8 H-Pro-Ala-Glu-Asp-Leu-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Leu-Thr-Arg-Pro-Arg-Tyr-NH2 500µg 1mg SBP0229 - Neuropeptide Y (18-36) MW: 2457.2 H-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2 Balasubramanian, A. et al. (1990) J. Biol. Chem. 265, 14724. 500µg 1mg SBP0230 - Neuropeptide Y (22-36) MW: 1903.4 H-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2 Ishiguro, T. et al. (1988) Chem. Pharm. Bull. 36, 2720. 1mg 5mg SBP0231 - [D-Tyr27&36,D-Thr32]-Neuropeptide Y (27-36) MW: 1338.7 H-D-Tyr-Ile-Asn-Leu-Ile-D-Thr-Arg-Gln-Arg-D-Tyr-NH2 When the tyrosine and threonine residues of the C-terminal decapeptide of NPY are replaced by their D-isomers, the peptide acts as an effective antagonist of NPY action on feeding when injected into the paraventricular nucleus (PVN) or ventromedial hypothalamus (VMH) 15 minutes before NPY. It also exhibits anorexic action, reducing the eating pattern of rats deprived of food in a dose-dependent manner. Myers, R.D. et al. (1995) Brain Res. Bull. 37, 237: Roscoe, A.K. et al. (1995) Peptides 16, 1411. 500µg 1mg Neurotensin and Related Peptides SBP0232 - N-Acetyl-Neurotensin (8-13) MW: 859.1 Ac-Arg-Arg-Pro-Tyr-Ile-Leu-OH Garnier, L. et al. (1982) Eur. J. Pharmacol. 24, 117. 5mg 25mg Orexins and Related Peptides SBP0233 - Orexin A, human MW: 3562 pGlu-Pro-Leu-Pro-Asp-Cys-Cys-Arg-Gln-Lys-Thr-Cys-Ser-Cys-Arg-Leu-Tyr-Glu-Leu-Leu-His-Gly-Ala-Gly-Asn-His-Ala-Ala-Gly-Ile-Leu-Thr-Leu-NH2 (Cys6-12, Cys7-14, dicyclic) Orexin A and orexin B are novel hypothalamic neuropeptides discovered by Sakuria et al. (1998) during a search for ligands for orphan G-protein coupled cell surface receptors. These peptides, whose structures are unrelated to any previously known regulatory peptides, are generated by specific proteolytic processing of the single precursor protein prepro-orexin. When administered centrally to rats, these peptides increase prepro-orexin mRNA levels and stimulate food consumption. When food intake was limited, orexin levels increased. They probably play an important role in the physiology of feeding behaviour. Sakurai, T. et al. (1998) Cell 92, 573. 500µg 1mg SBP0234 - Orexin B, human MW: 2899.9 H-Arg-Ser-Gly-Pro-Pro-Gly-Leu-Gln-Gly-Arg-Leu-Gln-Arg-Leu-Leu-Gln-Ala-Ser-Gly-Asn-His-Ala-Ala-Gly-Ile-Leu-Thr-Met-NH2 Orexin A and orexin B are novel hypothalamic neuropeptides discovered by Sakuria et al. (1998) during a search for ligands for orphan G-protein coupled cell surface receptors. These peptides, whose structures are unrelated to any previously known regulatory peptides, are generated by specific proteolytic processing of the single precursor protein prepro-orexin. When administered centrally to rats, these peptides increase prepro-orexin mRNA levels and stimulate food consumption. When food intake was limited, orexin levels increased. They probably play an important role in the physiology of feeding behaviour. Sakurai, T. et al. (1998) Cell 92, 573 500µg 1mg Oxytocin and Related Peptides SBP0235 - Oxytocin MW: 1007.4 H-Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 (Cys1-6, cyclic) du Vigneaud, V. et al. (1953) J. Biol. Chem. 205, 949; Thornton, S. et al. 81992) Exp. Physiol. 77, 293. 5mg 25mg SBP0236 - Carbetocin (2-O-methyltyrosine)-de-amino-1-carbaoxytocin MW: 988.1 (CH2)α-CO-Tyr(Me)-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 ((CH2)α -CO1, Cys6, cyclic) Jost, K (1987) CRC Handbook of Neurohypophyseal Hormone Analogs (eds.: Jost, Lebl & Brtnik; CRC Press Inc.), Vol. II, Part 2, p. 91 5mg 25mg Pancreatic Polypeptides (PP) SBP0237 - Pancreatic Polypeptide, human MW: 4182 H-Ala-Pro-Leu-Glu-Pro-Val-Tyr-Pro-Gly-Asp-Asn-Ala-Thr-Pro-Glu-Gln-Met-Ala-Gln-Tyr-Ala-Ala-Asp-Leu-Arg-Arg-Tyr-Ile-Asn-Met-Leu-Thr-Arg-Pro-Arg-Tyr-NH2 500µg 1mg SBP0238 - Pancreatic Polypeptide, rat MW: 4399.5 H-Ala-Pro-Leu-Glu-Pro-Met-Tyr-Pro-Gly-Asp-Tyr-Ala-Thr-His-Glu-Gln-Arg-Ala-Gln-Tyr-Glu-Thr-Gln-Leu-Arg-Arg-Tyr-Ile-Asn-Thr-Leu-Thr-Arg-Pro-Arg-Tyr-NH2 500µg 1mg Parathyroid Hormone (PTH) and Related Peptides SBP0239 - Parathyroid Hormone (1-37), human MW: 4401.6 H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-Val-Ala-Leu-OH 500µg 1mg SBP0240 - Parathyroid Hormone (1-34), human MW: 4118.4 H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH Takai, T. et al. (1979) Peptide Chemistry 1978, 189; Slovik, D. M. et al. (1986) J. Bone & Mineral Res. 1, 377. 500µg 1mg SBP0241 - Parathyroid Hormone (1-34), rat MW: 4059.2 H-Ala-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Ala-Ser-Val-Glu-Arg-Met-Gln-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH Keutmann, H.T. et al. (1985) Endocrinology 117, 1230. 500µg 1mg Peptide YY (PYY) and Related Peptides SBP0242 - Peptide YY, human MW: 4310.4 H-Tyr-Pro-Ile-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-Ala-Ser-Pro-Glu-Glu-Leu-Asn-Arg-Tyr-Tyr-Ala-Ser-Leu-Arg-His-Tyr-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2 Tatemoto, K. et al. (1988) Biochem. Biophys. Res. Commun. 157, 713. 500µg 1mg SBP0243 - [Leu31,Pro34]-Peptide YY, human MW: 4293.3 H-Tyr-Pro-Ile-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-Ala-Ser-Pro-Glu-Glu-Leu-Asn-Arg-Tyr-Tyr-Ala-Ser-Leu-Arg-His-Tyr-Leu-Asn-Leu-Leu-Thr-Arg-Pro-Arg-Tyr-NH2 500µg 1mg SBP0244 - [Pro34]-Peptide YY, human MW: 4279.3 H-Tyr-Pro-Ile-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-Ala-Ser-Pro-Glu-Glu-Leu-Asn-Arg-Tyr-Tyr-Ala-Ser-Leu-Arg-His-Tyr-Leu-Asn-Leu-Val-Thr-Arg-Pro-Arg-Tyr-NH2 500µg 1mg SBP0245 - Peptide YY(3-36), human MW: 4050 H-Ile-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-Ala-Ser-Pro-Glu-Glu-Leu-Asn-Arg-Tyr-Tyr-Ala-Ser-Leu-Arg-His-Tyr-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2 Eberlein, G.A. et al. (1989) Peptides 10, 797; Grandt, D. et al. (1992) Regul. Peptides 40, 161. 500µg 1mg SBP0246 - Peptide YY, porcine, rat MW: 4241.2 H-Tyr-Pro-Ala-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-Ala-Ser-Pro-Glu-Glu-Leu-Ser-Arg-Tyr-Tyr-Ala-Ser-Leu-Arg-His-Tyr-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2 Tatemoto, K. (1982) Proc. Soc. Natl. Acad. Sci. USA 79, 2514. 500µg 1mg SBP0247 - Peptide YY (13-36), porcine, rat MW: 3014.7 H-Ser-Pro-Glu-Glu-Leu-Ser-Arg-Tyr-Tyr-Ala-Ser-Leu-Arg-His-Tyr-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2 Wahlestedt, C. et al. (1986) Regul. Peptides 13, 307; Walker, M.W. et al. (1988) Mol. Pharmacol. 34, 779. 500µg 1mg PHI and PHM Peptides SBP0248 - PHI-27, porcine MW: 2995.8 H-His-Ala-Asp-Gly-Val-Phe-Thr-Ser-Asp-Phe-Ser-Arg-Leu-Leu-Gly-Gln-Leu-Ser-Ala-Lys-Lys-Tyr-Leu-Glu-Ser-Leu-Ile-NH2 Tatemoto, K. et al. (1981) Proc. Soc. Acad. Sci. USA 78, 6603. 500µg 1mg SBP0249 - PHI-27, rat MW: 3011.8 H-His-Ala-Asp-Gly-Val-Phe-Thr-Ser-Asp-Tyr-Ser-Arg-Leu-Leu-Gly-Gln-lle-Ser-Ala-Lys-Lys-Tyr-Leu-Glu-Ser-Leu-Ile-NH2 Nishijawa, H. et al. (1985) FEBS Letters 183, 55. 500µg 1mg Pituitary Adenylate Cyclase Activating Polypeptides (PACAP) and Related Peptides SBP0250 - PACAP (1-38), human, ovine, rat MW: 4535 H-His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-Gly-Lys-Arg-Tyr-Lys-Gln-Arg-Val-Lys-Asn-Lys-NH2 Miyata, A. et al. (1989) Biochem. Biophys. Res. Commun. 164, 567; Ogi, K. et al. (1990) Biochem. Biophys. Res. Commun. 173, 1271. 500µg 1mg SBP0251 - PACAP (1-27) Amide, human, ovine, rat MW: 3148.1 H-His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-NH2 Miyata, A. et al. (1989) Biochem. Biophys. Res. Commun. 164, 567 500µg 1mg SBP0252 - PACAP (6-38), human, ovine, rat MW: 4025.4 H-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-Gly-Lys-Arg-Tyr-Lys-Gln-Arg-Val-Lys-Asn-Lys-NH2 Robberecht, P. et al. (1992) Eur. J. Biochem. 207, 239; Robberecht, P. et al. (1992) Molec. Pharmacol. 42, 347. 500µg 1mg SBP0253 - PACAP (6-27) Amide, human, ovine, rat MW: 2638.8 H-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-NH2 Robberecht, P. et al. (1991) FEBS Letters 186, 133. 500µg 1mg Prolactin Releasing Peptides (PrRP) and Related Peptides SBP0254 - Prolactin Releasing Peptide-31 (PrRP-31), bovine MW: 3576.5 H-Ser-Arg-Ala-His-Gln-His-Ser-Met-Glu-Ile-Arg-Thr-Pro-Asp-Ile-Asn-Pro-Ala-Trp-Tyr-Ala-Gly-Arg-Gly-Ile-Arg-Pro-Val-Gly-Arg-Phe-NH2 PrRP-31 and PrRP-20 are the first reported hypothalamic peptides that exclusively stimulate the release of prolactin from the pituitary without affecting that of other known hypophyseal hormones. Interestingly, the discovery of these peptides is an example of an orphan peptide receptor being used to identify its own ligand. Working backwards from the human orphan receptor, hGR3, Hinuma et al. (1998) identified a peptide ligand in bovine hypothalamic extracts. After isolation of the respective cDNA in bovine brain, they were able to identify the 31-amino acid peptide (PrRP-31) and 20-amino acid fragment (PrRP-20) corresponding to this sequence. The peptide sequences are reported to be highly conserved in other species (human, rat). PrRP-31 has been shown to stimulate prolactin release from a rat pituitary RC-4B/C adenoma cells, from anterior pituitary cells from lactating rats, and from rat pituitary cells in a perfusion assay. Hinuma, S. et al. (1998) Nature 393, 272. 500µg 1mg SBP0255 - Prolactin Releasing Peptide-31 (24-31), bovine; PrRP-31 (24-31), bovine MW: 1347.8 H-Tyr-Ala-Gly-Arg-Gly-Ile-Arg-Pro-Val-Gly-Arg-Phe-NH2 C-Terminal fragment of bovine prolactin-releasing peptide suitable for iodination. 1mg 5mg SBP0256 - Prolactin Releasing Peptide-20 (PrRP-20), bovine MW: 2242.8 H-Thr-Pro-Asp-Ile-Asn-Pro-Ala-Trp-Tyr-Ala-Gly-Arg-Gly-Ile-Arg-Pro-Val-Gly-Arg-Phe-NH2 PrRP-20 is believed to be a naturally occurring truncated form of PrRP-31 corresponding to the C-terminal 20 amino acids of that peptide. Hinuma, S. et al. (1998) Nature 393, 272. 500µg 1mg Protease Inhibitors SBP0257 -Eglin c (60-63) Methyl Ester MW: 445.5 H-Thr-Asn-Val-Val-OMe Tsuboi, S. et al. (1979) Chem. Pharm. Bull. 39, 184. 5mg 25mg Protease Substrates SBP0258 - Urokinase substrate, Z-γ-Glu(tBu)-Gly-Arg-pNA MW: 670.7 Z-γ -Glu(tBu)-Gly-Arg-pNA A substrate for urokinase Harvey, S.R. et al. (1988) Clin. Exptl. Metastasis 6, 431. This peptide is supplied as the acetate salt. 5mg 25mg SBP0259 - Mca-Pro-Leu-Gly-Leu-Dpr(Dnp)-Ala-Arg-NH2 MW: 1093.2 Mca-Pro-Leu-Gly-Leu-Dpr(Dnp)-Ala-Arg-NH2 Knight, C.G. et al. (1992) FEBS Letters 296, 263; Galis, Z.S. et al. (1995) FASEB J. 9, 974. 1mg 5mg SBP0260 - Suc-Ala-Ala-Pro-Phe-pNA MW: 640.6 Suc-Ala-Ala-Pro-Phe-pNA DelMar, E.G. et al. (1979) Anal. Biochem. 99, 316; Nakajima, K. et al. (1979) J. Biol. Chem. 254, 4027. 50mg 250mg Protein Kinase Related Peptides SBP0261 - Casein Kinase II Receptor Peptide MW: 1206.3 H-Arg-Arg-Glu-Glu-Glu-Thr-Glu-Glu-Glu-OH Klarlund, J.K. & Czech, M.P. (1988) J. Biol. Chem. 263, 15872. 1mg 5mg SBP0262 - cGMP-Dependent Protein Kinase Substrate MW: 1575 H-Arg-Lys-Ile-Ser-Ala-Ser-Glu-Phe-Asp-Arg-Pro-Leu-Arg-OH 1mg 5mg SBP0263 - MAP Kinase Phosphorylation Substrate EGF Receptor (661-681) MW: 2318.8 H-Lys-Arg-Glu-Leu-Val-Glu-Pro-Leu-Thr-Pro-Ser-Gly-Glu-Ala-Pro-Asn-Gln-Ala-Leu-Leu-Arg-OH 1mg 5mg SBP0264 - Protein Kinase C (19-31) MW: 1544 H-Arg-Phe-Ala-Arg-Lys-Gly-Ala-Leu-Arg-Gln-Lys-Asn-Val-OH House, C. & Kemp, B.E. (1987) Science 238, 1726. Alexander, D.R. et al. (1989) Biochem. J. 260, 893. 1mg 5mg SBP0265 - Protein Kinase C Substrate KRTLRR MW: 829.1 H-Lys-Arg-Thr-Leu-Arg-Arg-OH Heasley, L. & Johnson, G.L. (1989) J. Biol. Chem. 264, 8646. 5mg 10mg SBP0266 - AMP-activated kinase substrate, SAMS MW: 1779.15 H-His-Met-Arg-Ser-Ala-Met-Ser-Gly-Leu-His-Leu-Val-Lys-Arg-Arg-OH Phosphorylated by AMPK. Used as an assay for AMPK. Carling Et al (1989) Eur.J.Biochem. 186 129. 500µg 1mg SBP0267 - Death-Associated Protein Kinase (DAPK) Substrate MW: 1578.82 H-Lys-Lys-Arg-Pro-Gln-Arg-Arg-Tyr-Ser-Asn-Val-Phe-OH Synthetic peptide substrate for death associated protein kinase. Velentza et al (2001) J.Biol.Chem. 276 38956. 1mg 5mg SBP0268 - Myosin Light Chain Kinase Inhibitor Peptide MW: 1444.79 H-Lys-Arg-Arg-Trp-Lys-Lys-Asn-Phe-Ile-Ala-Val-NH2 Competitive myosin light chain kinase inhibitor, (Ki = 1-2.2µM). Also binds calmodulin. Kemp et al (1987) J.Biol.Chem. 262 2542. 1mg 5mg SBP0269 - Myosin Light Chain Kinase Inhibitor Peptide 18 MW: 1324.64 H-Arg-Lys-Lys-Tyr-Lys-Tyr-Arg-Arg-Lys-NH2 Selective competitive inhibitor of myosin light chain kinase (IC50=50nm). Displays 4000-fold selectivity over CaM kinase II and does not inhibit PKA. Lukas et al (1999) J.Med.Chem. 42 910. 1mg 5mg SBP0270 - CaM kinase II Inhibitor Peptide MW: 3374.08 H-Met-His-Arg-Gln-Glu-Thr-Val-Asp-Cys-Leu-Lys-Lys-Phe-Asn-Ala-Arg-Arg-Lys-Leu-Lys-Gly-Ala-Ile-Leu-Thr-Thr-Met-Leu-Ala-OH Inhibitor of Ca2+-indipendant form of CaM kinase II found in post synaptic densities (IC50=3.6µM). Rich et al (1989) J.Neurochem. 53 807. 1mg 5mg SBP0271 - SH2 Binding Domain Inhibitor Ac-Tyr(PO4)-Glu-Glu-Ile-Glu-OH MW: 803.71 Ac-Tyr(PO4)-Glu-Glu-Ile-Glu-OH Binds SH2 domain (IC50=1.35µM). Additionally blocks binding of SH2 domain constructs to platelet derived growth factor kinase. Shahripour et al (1996) Bioorg.Med.Chem.Lett 6 1209. 1mg 5mg Sauvagine and Related Peptides SBP0272 - Sauvagine MW: 4599.9 pGlu-Gly-Pro-Pro-Ile-Ser-Ile-Asp-Leu-Ser-Leu-Glu-Leu-Leu-Arg-Lys-Met-Ile-Glu-Ile-Glu-Lys-Gln-Glu-Lys-Glu-Lys-Gln-Gln-Ala-Ala-Asn-Asn-Arg-Leu-Leu-Leu-Asp-Thr-Ile-NH2 Sauvagine is a biologically active peptide isolated from the skin of the tropical frog Phyllomedusa sauvagei. It possesses a number of pharmacological and endocrinological actions, affecting diuresis and the cardiovascular system. Montecucchi & Henschen (1981) Int. J. Peptide Protein. Res. 18, 113; Vale et al. (1981) Science 213, 1394. 500µg 1mg SBP0273 - [Tyr0]-Sauvagine MW: 4781.1 H-Tyr-Glu-Gly-Pro-Pro-Ile-Ser-Ile-Asp-Leu-Ser-Leu-Glu-Leu-Leu-Arg-Lys-Met-Ile-Glu-Ile-Glu-Lys-Gln-Glu-Lys-Glu-Lys-Gln-Gln-Ala-Ala-Asn-Asn-Arg-Leu-Leu-Leu-Asp-Thr-Ile-NH2 500µg 1mg SBP0274 - Anti-Sauvagine 30 MW: 3651.3 H-D-Phe-His-Leu-Leu-Arg-Lys-Met-Ile-Glu-Ile-Glu-Lys-Gln-Glu-Lys-Glu-Lys-Gln-Gln-Ala-Ala-Asn-Asn-Arg-Leu-Leu-Leu-Asp-The-Ile-OH This peptide, which is a conformationally constrained analogue of sauvagine, is a selective ligand for CRF type 2ß receptors and has been shown to suppress agonist-induced adenylate cyclase activity in HEK cells expressing murine CRF type 2ß receptors. Rühmann, A et al. (1998) Proc. Natl. Acad. Sci. USA 95, 15264 500µg 1mg Secretins SBP0275 - Secretin, human MW: 3039.8 H-His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Glu-Leu-Ser-Arg-Leu-Arg-Glu-Gly-Ala-Arg-Leu-Gln-Arg-Leu-Leu-Gln-Gly-Leu-Val-NH2 Carlquist, M. et al. (1985) IRC Med. Science 13, 217; Ohta, M. et al. (1992) Biochem. Biophys. Res. Commun. 183, 390. 1mg 5mg SBP0276 - Secretin, porcine MW: 3055.9 H-His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Glu-Leu-Ser-Arg-Leu-Arg-Asp-Ser-Ala-Arg-Leu-Gln-Arg-Leu-Leu-Gln-Gly-Leu-Val-NH2 Bodansky, M. et al. (1967) J. Amer. Chem. Soc. 89, 6753. 1mg 5mg Somatostatin and Related Peptides SBP0277 - Somatostatin 28 (cyclic) MW: 3149 H-Ser-Ala-Asn-Ser-Asn-Pro-Ala-Met-Ala-Pro-Arg-Glu-Arg-Lys-Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH (Cys17-28, cyclic) Pradayrol, L. et al. (1980) FEBS Letters, 109, 55; Schally, A.V. et al. (1980) Proc. Soc. Natl. Acad. Sci. USA 77, 4489. 500µg 1mg SBP0278 - [Tyr0]-Somatostatin 28 (cyclic) MW: 3312.2 H-Tyr-Ser-Ala-Asn-Ser-Asn-Pro-Ala-Met-Ala-Pro-Arg-Glu-Arg-Lys-Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH (Cys18-29, cyclic) 500µg 1mg SBP0279 - Somatostatin (cyclic) MW: 1638.1 H-Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH (Cys3-14, cyclic) Brazeau, P. et al. (1973) Science 179, 77; Reubi, J.C. et al. (1982) Endocrinology 110, 1049; Gustaffson, S. et al. (1978) Biochem. Biophys. Res. Commun. 82, 1229; White, R.E. et al. (1991) Nature 351, 570. 5mg 25mg SBP0280 - [Tyr0]-Somatostatin (cyclic) MW: 1801.4 H-Tyr-Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH (Cys4-15, cyclic) 500µg 1mg Substance P and Related Peptides SBP0281 - Substance P MW: 1347.8 H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 Chang, M.M. et al. (1971) Nature 232, 86; Pernow, B. (1983) Pharmacol. Rev. 35, 85; Roberts, A.I. et al. (1982) Cell Immunol. 141, 457. 5mg 25mg Substance P Antagonists SBP0282 - [D-Arg1, D-Phe5, D-Trp7&9, Leu11]-Substance P MW: 1517 H-D-Arg-Pro-Lys-Pro-D-Phe-Gln-D-Trp-Phe-D-Trp-Leu-Leu-NH2 Tsau, K. et al. (1985) Eur. J. Pharmacol. 110, 155; Heinz-Erian, P. et al. (1986) Gastroenterology 90, 1455; Fabregat, I. & Razengurt, E.T. (1990) J. Cell Physiol. 145, 88. 1mg 5mg SBP0283 - [D-Arg1,D-Trp7&9,Leu11]-Substance P Spantide I MW: 1496.8 H-D-Arg-Pro-Lys-Pro-Gln-Gln-D-Trp-Phe-D-Trp-Leu-Leu-NH2 Folkers, K. et al. (1984) Br. J. Pharmacol. 83, 449; Hakanson, R. et al. (1990) Regul. Peptides 31, 75. 1mg 5mg Thymopoietin (TP) Fragments SBP0284 - Thymopentin MW: 679.8 H-Arg-Lys-Asp-Val-Tyr-OH 1mg 5mg Thymosin and Fragments SBP0285 - Thymosin-α1 MW: 3108.7 Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH Sztein, M.B. & Goldstein, A.L. (1986) Springer Semin. Immunopathol. 9, 1. 500µg 1mg SBP0286 - [Ac-Tyr0]-Thymosin-α1 MW: 3271.9 Ac-Tyr-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH 500µg 1mg Urotensins SBP0287 - Urotensin II, human MW: 1387.2 H-Glu-Thr-Pro-Asp-Cys-Phe-Trp-Lys-Tyr-Cys-Val-OH (Cys5-10, cyclic) Urotensin II is located in human vascular and cardiac tissue. It is the most potent vasoconstrictor known at the present time (1999), being an order of magnitude more potent than endothelin-1. Immunoreactivity has also been observed in CNS and endocrine tissues. A human orphan receptor for urotensin II has been described.  Coulouarn Y. et al. (1998) Proc. Soc. Acad. Sci. USA 95, 15803; Ames R.S. et al. (1999) Nature 401, 282. 1mg 5mg SBP0288 - Urotensin II, teleost fish MW: 1361.8 H-Ala-Gly-Thr-Ala-Asp-Cys-Phe-Trp-Lys-Tyr-Cys-Val-OH (Cys6-11, cyclic) Urotensin II is a vasoactive peptide with some homology to somatostatin. It was originally found in the caudal neurosecretory system of the teleost fish, Gillichthys mirabilis. Pearson, D. et al. (1980) Proc. Soc. Natl. Acad. Sci. USA 77, 5021 1mg 5mg Vasoactive Intestinal Peptide (VIP) and Related Peptides SBP0289 - Vasoactive Intestinal Peptide, human, porcine, rat MW: 3326.2 H-His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2 Bodanszky, M. et al. (1974) J. Amer. Chem. Soc. 96, 4973; Said, S. I. et al. (1970) Science 169, 1217; Segura, J.J. et al. (1992) Regul. Peptides 37, 145. 500µg 1mg SBP0290 - [D-Phe2]-Vasoactive Intestinal Peptide, human, porcine, rat MW: 3386.3 H-His-D-Phe-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2 Robberecht, P. et al. (1986) Eur. J. Biochem. 159, 45. 500µg 1mg SBP0291 - [p-chloro-D-Phe6,Leu17]-VIP, human, porcine, rat MW: 3342.2 H-His-Ser-Asp-Ala-Val-p-Cl-D-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Leu-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2 VIP Antagonist Pandol, S.J. et al. (1986) Am. J. Physiol. 250, G553. 500µg 1mg SBP0292 - Vasoactive Intestinal Peptide (6-28), human, porcine, rat MW: 2816.6 H-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2 Fishbein, V.A. et al. (1994) Peptides 15, 95. 500µg 1mg SBP0293 - Lys-Pro-Arg-Arg-Pro-Tyr-VIP (7-28), human, porcine, rat MW: 3467.4 H-Lys-Pro-Arg-Arg-Pro-Tyr-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2 VIP Antagonist Gozes, I. et al. (1989) Endocrinology 125, 2945. 500µg 1mg SBP0294 - Vasoactive Intestinal Peptide (10-28), human, porcine, rat MW: 2339.1 H-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2 Turner, J.T. et al. (1986) Peptides 7, 849; Cox, H.M. & Cuthbert. A.W. (1989) Regul. Peptides 26, 127. 1mg 5mg SBP0295 - [pGlu16]-Vasoactive Intestinal Peptide (16-28), human, porcine, rat MW: 1504 pGlu-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2 Bodanszky, M. et al. (1979) Bioorg. Chem. 8, 399. 1mg 5mg Vasopressin, Vasotocin and Related Peptides SBP0296 - [Arg8]-Vasopressin AVP MW: 1084.4 H-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2 (Cys1-6, cyclic) Bell, J. et al. (1992) Int. J. Immunopharm. 14, 92. 5mg 25mg SBP0297 - [Lys8]-Vasopressin MW: 1056.4 H-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-NH2 (Cys1-6, cyclic) Zaoral, M. et al. (1967) Coll. Czech Chem. Commun. 32, 1242. 5mg 25mg SBP0298 - [Phe2,Lys8]-Vasopressin Felypressin MW: 1040.4 H-Cys-Phe-Phe-Gln-Asn-Cys-Pro-Lys-Gly-NH2 (Cys1-6, cyclic) 5mg 25mg SBP0299 - [Phenylacetyl1,O-D-Tyr(Et)2,Val4,Lys6,Arg8,Tyr9]-Vasopressin MW: 1231.5 Phaa-D-Tyr(Et)-Phe-Val-Asn-Lys-Pro-Arg-Tyr-NH2 1mg 5mg SBP0300 - [d(CH2)51, D-Ile2,Ile4,Arg8,Ala9]-Vasopressin MW: 1086.4 Pmp-D-Ile-Phe-Ile-Asn-Cys-Pro-Arg-Ala-NH2 (Pmp1-Cys6, cyclic) Manning, M. & Sawyer, W.H. (1989) J. Lab. Clin. Med. 114, 617. 1mg 5mg SBP0301 - [d(CH2)51,Tyr(Me)2,Thr4,Orn8,Tyr9]-Vasotocin MW: 1154.5 Pmp-Tyr(Me)-Ile-Thr-Asn-Cys-Pro-Orn-Tyr-NH2 (Pmp1-Cys6, cyclic) Elands, J. et al. (1987) Eur. J. Pharmacol. 147, 197. 1mg 5mg SBP0302 - [d(CH2)51,D-Tyr(Et)2,Arg3&8,Val4]-Vasopressin [d(CH2)51,D-Tyr(Et)2,Arg3,Val4]-AVP MW: 1145.4 Pmp-Tyr(Et)-Arg-Val-Asn-Cys-Pro-Arg-Gly-NH2 Arginine-vasopressin (AVP) has both vasoconstricting and vasodilating actions. This hypotensive AVP analogue exhibits selective vasodepressor activity that is mediated by neither V1a, V2 or oxytocin receptors nor by NO. This analogue represents one of a new class of pharmacological tools that can be used for investigating the complex cardiovascular actions of AVP and may form the basis for the development of novel antihypertensive agents. Chan, W.Y. et al. (1998) Br. J. Pharmacol. 125, 803. 5mg 25mg SBP0303 - [d(CH2)51, Tyr(Me)2, Arg8]-Vasopressin Manning Compound MW: 1151.4 Pmp-Tyr(Me)-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2 (Pmp1-Cys6, cyclic) Kruszynski, M. et al. (1980) J. Med. Chem. 23, 364. 1mg 5mg SBP0304 - [Arg8]-Vasotocin MW: 1050.4 H-Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Arg-Gly-NH2 (Cys1-6, cyclic) Acher, R. et al. (1960) Biochim. Biophys. Acta 42, 379. 5mg 25mg SBP0305 - [Lys8]-Vasotocin LVT MW: 1022.3 H-Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Lys-Gly-NH2 (Cys1-6, cyclic) 5mg 25mg Alphabetical Index of Peptides ACTH (5-10) ACTH (4-10), [Pro8&10,Gly9]- ACTH (1-39), human ACTH (1-39), porcine ACTH (34-39) ACTH (1-13) Amide, Acetyl- ACTH (1-13) Amide ACTH (4-10), [D-Arg8]- ACTH (1-24), human Adrenocorticotrophic Hormone (ACTH) and Related Peptides Alytesin AMP-Activated Kinase Substrate, SAMS AMPA Type Glutamate Receptors and Related Peptides Amylin, rat Amylin (8-37), rat Amylin (8-37), human, N-Acetyl- Amylin (8-37), rat , N-Acetyl- Amylin (8-37), human Amylin, human Amylin, Pre-pro Amylin (Diabetes Associated Peptide Amide; DAP Amide) and Related Peptides Amyloid P Component (27-38) Amide, Tyr- Amyloid P Component (33-38) Amide, Tyr- Amyloid Precursor Protein ß-Secretase Inhibitor Amyloid ß-Protein (25-35) Amyloid ß-Protein Fragments Amyloid P Component Hexapeptide, [Tyr0]- Amyloid P Component Dodecapeptide, [Tyr0]- Amyloid ß-Protein (1-40) Amyloid ß-Protein (1-42) Amyloid ß-Protein (1-43) ANF (1-28), human, porcine ANF (1-28), rat Angiotensin II, human (Octapeptide) Angiotensin I, [Des-Leu10]- Angiotensin I (1-9) Angiotensin and Related Peptides Angiotensin II, [Asn1,Val5]- Angiotensin II, [Sar1]- Angiotensin I, human (Decapeptide) ANP, human, Thr-Ala-Pro-Arg- Antisauvagine 30 Astressin Atrial Natriuretic Peptide (1-28), rat Atrial Natriuretic Peptide (ANP) and Related Peptides Atrial Natriuretic Peptide (1-28), human, porcine AVP, [d(CH2)51,D-Tyr(Et)2,Arg3,Val4]- AVP Big Endothelin-1, human BNP-32, human Bombesin (6-14), [D-Phe6,ß-Ala11,Phe13,Nle14]- Bombesin (6-14), [D-Tyr6,ß-Ala11,Phe13,Nle14]- Bombesin and Related Peptides Bombesin Bombesin, [Leu13-ψ(CH2NH)-Leu14]- BQ123 27 Bradykinin, [Des-Arg9,Lys0]- Bradykinin and Related Peptides Bradykinin Brain Natriuretic Peptide, human Brain Natriuretic Peptide (BNP) and Related Peptides Buserelin Buserelin, [D-His2]- C7 C-Peptide (1-35), human C-Peptide (3-33), human C-Peptide (1-35), human, [Tyr0]- C-Peptide (3-35), human C-Peptide and Related Peptides Caerulein, non-sulfated Caerulein, sulphated Caerulein and Related Peptides Calcitonin and Related Peptides Calcitonin Gene Related Peptide (CGRP) and Related Peptides Calcitonin, salmon Calcitonin, rat Calcitonin, human Calcitonin, eel CaM Kinase II Inhibitor Peptide Carbetocin Casein Kinase II Receptor Peptide Caspase Inhibitors Caspase 1 Inhibitor Ac-YVAD aldehyde Caspase 3 Inhibitor Ac-DEVD aldehyde Caspase 6 Inhibitor Ac-VEID aldehyde Caspase 8 Inhibitor Ac-IETD aldehyde Caspase Substrates Caspase 1 Substrate Ac-YEVD-AMC, Fluorogenic Caspase 1 Substrate Ac-YVAD-AMC, Fluorogenic Caspase 3 Substrate Ac-DEVD-AFC, Fluorogenic Caspase 3 Substrate Ac-DEVD-AMC, Fluorogenic Caspase 3 Substrate Ac-DEVD-pNA, Chromogenic Caspase 4 Substrate Ac-LEVD-pNA, Chromogenic Caspase 6 Substrate Ac-VEID-AMC, Fluorogenic Caspase 8 Substrate Ac-IETD-AMC, Fluorogenic CCK Octapeptide (CCK-8), sulphated CCK Octapeptide (CCK-8), non-sulphated cGMP-Dependent Protein Kinase Substrate CGRP, chicken CGRP, human, α- CGRP, human, [Cys(Et)2&7]-α - CGRP, human, [Cys(Acm)2&7]-α - CGRP (8-37), human, α - CGRP, rat, α - CGRP (32-37), rat CGRP (22-37), rat, [Tyr22]-α - CGRP-1, human Charybdotoxin Cholecystokinin (26-33), non-sulphated Cholecystokinin (CCK) and Related Peptides Cholecystokinin (26-33), sulphated Connexin Peptides Corticotropin Releasing Factor (CRF) and Related Peptides Corticotropin Releasing Factor, bovine Corticotropin Releasing Factor, human, rat, [Tyr0]- Corticotropin Releasing Factor (9-41), α -Helical Corticotropin Releasing Factor (12-41), human, rat, [D-Phe12, Nle21&38, C-α-Me-Leu37]- Corticotropin Corticotropin Releasing Factor, ovine Corticotropin Releasing Factor, human, rat Corticotropin Releasing Factor (12-41), cyclic lactam, human, rat, [D-Phe12, Nle21&38, Glu30, Lys33]- Corticotropin Releasing Factor (6-33) Amide, human, rat Corticotropin Releasing Factor (12-41), α-Helical CRF (12-41), α-Helical CRF (12-41), human, rat, [D-Phe12, Nle21&38, C-α-Me-Leu37]- CRF (12-41), cyclic lactam, human, rat, [D-Phe12, Nle21&38, Glu30, Lys33]- CRF (9-41), α-Helical DAKLI DAPK Substrate Dalargin Death Associated Protein Kinase, (DAPK), Substrate Deslorelin Diabetes-associated Peptide (DAP) Amide, human Diabetes-associated Peptide (DAP) Amide, rat Dynorphin A (1-13) Dynorphin A (1-5) Dynorphin A (1-13)-Gly-NH(CH2)5NH2, [Arg11&13]- Dynorphin B Dynorphin A Dynorphin (Neo-Endorphin) and Related Peptides EGF Receptor (661-681) Eglin c (60-63) Methyl Ester Endomorphin-1 Endomorphin-2 Endomorphins and Related Peptides Endorphin, human, ß- Endorphin, porcine, ß- Endorphins, Lipotropins, Pro-Opiomelanocortin Fragments and Related Peptides Endothelin (8-21), N-Succinyl-[Glu9, Ala11&15]- Endothelin 1, dog, human, porcine, rat Endothelins and Related Peptides Enkephalin, [Leu5]- Enkephalin, [D-Ala2,Leu5,Arg6]- Enkephalin and Related Peptides Enkephalin Amide, [Met5]- Enkephalin Amide, [Leu5]- Enterostatin, human Enterostatins Exendin 3 Exendin 3 (9-39) Exendin 4 Exendin 4 (3-39) Exendins and Fragments Felypressin Fibrinogen Fragments and Related Peptides Fibrinopeptide A, human Fibronectin Fragments and Related Peptides Fluorogenic Caspase 3 Substrate Ac-DEVD-AMC Galanin (1-13) - Spantide-NH2 Galanin (1-13) - Bradykinin (2-9) Amide Galanin, rat Galanin and Related Peptides Galanin, human Galanin (1-13) - Substance P (5-11) Amide Galanin, porcine Galanin (1-13) - Pro2 (Ala-Leu)2-Ala Amide Galantide Gap18 Gap20 Gap26 Gap26 Scrambled Gap27 Cx37,43 Gap27 Cx37,43 Scrambled Gap27 Cx40 Gap27 Cx40 Scrambled Gastric Inhibitory Polypeptide (GIP), human Gastric Inhibitory Polypeptide (GIP) and Related Peptides Gastrin Releasing Peptide (GRP) and Related Peptides Gastrin (5-17), [Leu15]- Gastrin I, human Gastrin and Related Peptides Gastrin Releasing Peptide (GRP), human Gastrin I, rat Ghrelin, human Ghrelin, rat Ghrelin, rat, [Des-Gln14] Ghrelin, human, biotinyl Ghrelin, rat, biotinyl Ghrelin, rat, [Des-Gln14], biotinyl Ghrelin, human, [Des-octanoyl] Ghrelin, rat, [Des-octanoyl] Ghrelin, rat, [Des-Gln14, Des-octanoyl] GHRP6 GLP-1(7-36) Amide GLP-2, human Glucagon (1-29), bovine, human, porcine, [Des-His1,Des-Phe6,Glu9]- Glucagon and Related Peptides Glucagon (19-29), bovine, human, porcine Glucagon (1-29), bovine, human, porcine Glucagon-like Peptide 2, human Glucagon-Like Peptide 1 (7-36) Amide, human Glucagon-Like Peptide (GLP) and Related Peptides Gonadorelin Goserelin GPRP Fibrin Antipolymerant GRF (1-29) amide, human, [D-Tle2,Nle26]- GRF (1-29) amide, human, [D-Ala2]- GRF (1-29) amide, human, [D-Tle2]- GRGDS (Fibronectin Attachment Peptide) GRGDSPK (Fibronectin Attachment Peptide) Growth Factors and Related Peptides Growth Hormone Releasing Factor (1-29) Amide, human, [Nle26]- Growth Hormone Releasing Factor (1-29) Amide, human Growth Hormone Releasing Factor (1-44), human Growth Hormone Releasing Factors (GRF, GHRH) and Related Peptides Growth Hormone Releasing Factor (1-44), ovine Growth Hormone Releasing Factor (1-44), bovine HIV Protease Substrate III HIV Peptide gp120 (254-274) HIV Related Peptides HP-228 HPV 16-E7 HPV Peptides Iberiotoxin Interleukin 1ß Converting Enzyme Substrate II Interleukin Fragments and Related Peptides Interleukin-6 (88-121), human Ion Channel Modulators IRL 1620 Kallidin, [Des-Arg10]- Lecirelin Leptin Fragments and Related Peptides Leptin (22-56), human Leuprolide LHRH, human LHRH, [D-Trp6]- LHRH, [Des-Gly10,D-His2,D-Ser(tBu)6,Pro-NHEt9]- LHRH , [Des-Gly10, D-Leu6, Pro-NHEt9]- LHRH, [D-Ser(tBu)6,Aza-Gly10]- LHRH, [Des-Gly10,D-Ala6,Pro-NHEt9]- LHRH, [Des-Gly10,Pro-NHEt9]- LHRH, [Des-Gly10,D-Trp6,Pro-NHEt9]- LHRH, [D-Tle6,Pro-NHEt9]- LHRH, [D-Lys6]- LHRH, [Des-Gly10,D-Ser(tBu)6,Pro-NHEt9]- LHRH (1-5)-OMe LHRH, [D-Ala6]- LHRH-III, lamprey Lipotropin (61-91), human, ß- Luteinizing Hormone Releasing Hormone (LHRH) and Related Peptides LVT M40 Manning Compound MAP Kinase Phosphorylation Substrate Matrix Metalloproteinase (MMP) Substrates MBP 84-102 MBP 143-168 Mca-Pro-Leu-Gly-Leu-Dpr(DNP)-Ala-Arg-NH2 Melanocyte Stimulating Hormones (MSH) and Related Peptides Minigastrin, [Leu11]- MMP 2 and 9 Substrate DNP-PLGMWSR, Chromogenic MOG 1-22 MOG 34-56 MOG 64-86 MOG 74-96 Motilin, human, porcine Motilin and Related Peptides Motilin, human, porcine, [Leu13]- MSH, α- MSH, human, ß- MSH, γ1- MSH, γ2- MSH (5-13), [Met5,Pro6,D-Phe7,D-Trp9,Phe10]-α- MSH (4-13), cyclic, [N-Acetyl-Cys4,D-Phe7,Cys10]-α- MSH, [Nle4,D-Phe7]-α- MSH (4-10) Amide, [N-Acetyl-Nle4,Gln5,D-Phe7,D-Trp9]-α- MSH, [Des-Acetyl ]-α - MSH, [Nle4]-α - MSH (4-10) Amide (Asp5-Lys10, cyclic lactam), [N-Acetyl-Nle4,Asp5,D-2'-Nal7,Lys10]-α- MSH (4-10) Amide (Asp5-Lys10, cyclic lactam), [N-Acetyl-Nle4,Asp5,D-Phe7,Lys10]-α- MTII Myelin Basic Protein (84-102) Myelin Basic Protein (143-168) Myelin Oligodendrocyte Glycoprotein (1-22) Myelin Oligodendrocyte Glycoprotein (34-56) Myelin Oligodendrocyte Glycoprotein (64-86) Myelin Oligodendrocyte Glycoprotein (74-96) Myelin Proteins Myosin Light Chain Kinase Inhibitor Peptide Myosin Light Chain Kinase Inhibitor Peptide 18 Neoendorphin (1-5), α- Neurokinin A (4-10), [ß-Ala8]- Neurokinins, Neuromedins, Other Tachykinins and Related Peptides Neuromedin U8 Neuropeptide AF Neuropeptide FF-amide Neuropeptide SF Neuropeptide Y (NPY) and Related Peptides Neuropeptide Y, human, rat Neuropeptide Y, porcine Neuropeptide Y, porcine, [Pro34]- Neuropeptide Y, human, rat, Biotinyl- Neuropeptide Y (13-36), human, rat Neuropeptide Y (13-36), porcine Neuropeptide Y (22-36) Neuropeptide Y (18-36) Neuropeptide Y, porcine, Biotinyl- Neuropeptide Y, human, rat, [Leu31,Pro34]- Neuropeptide Y (3-36), porcine Neuropeptide Y (2-36), porcine Neuropeptide Y, porcine, [Leu31,Pro34]- Neuropeptide Y, porcine, [D-Trp32]- Neuropeptide Y (13-36), porcine, [Leu31,Pro34]- Neuropeptide Y, human, rat, [D-Trp32]- Neuropeptide Y (2-36), human, rat Neuropeptide Y (3-36), human, rat Neuropeptide Y (27-36), [D-Tyr27&36,D-Thr32]- Neuropeptide Y (13-36), human, rat, [Leu31,Pro34]- Neuropeptide Y (1-24) Amide, human Neurotensin and Related Peptides Neurotensin (8-13), N-Acetyl- Nociceptin (1-13) Amide Nociceptin (1-13) Amide, [Phe1-ψ(CH2-NH)-Gly2]- Nociceptin Orexin A, human Orexin B, human Orexins and Related Peptides Orphanin FQ Oxytocin and Related Peptides Oxytocin PACAP (6-38), human, ovine, rat PACAP (1-27) Amide, human, ovine, rat PACAP (6-27) Amide, human, ovine, rat PACAP (1-38), human, ovine, rat Pancreatic Polypeptides (PP) Pancreatic Polypeptide, rat Pancreatic Polypeptide, human Parathyroid Hormone (1-37), human Parathyroid Hormone (PTH) and Related Peptides Parathyroid Hormone (1-34), rat Parathyroid Hormone (1-34), human Pentagastrin Pep1-AGL Pep1-TGL Pep2-AVKI Pep2-EVKI Pep2m Pep2-SVKE Pep2-SVKI Pep4c Peptide YY, human, [Pro34]- Peptide YY(3-36), human Peptide YY (PYY) and Related Peptides Peptide YY, human, [Leu31,Pro34]- Peptide YY, human Peptide YY, porcine, rat Peptide YY (13-36), porcine, rat PHI and PHM Peptides PHI-27, rat PHI-27, porcine Pituitary Adenylate Cyclase Activating Polypeptides (PACAP) and Related Peptides PLP 41-58 PLP 184-199 PLP 190-209 Pompilidotoxin, ß- Preproglucagon (78-107) Amide, human Prodynorphin (207-223), human Prodynorphin (209-225), porcine Proinsulin (31-65), human Proinsulin (33-65), human Proinsulin (33-63), human Proinsulin (31-65), human, Tyr- Prolactin Releasing Peptide-31 (PrRP-31), bovine Prolactin Releasing Peptide-31 (24-31), bovine; PrRP- Prolactin Releasing Peptide-20 (PrRP-20), bovine Prolactin Releasing Peptides and Related Peptides Protease Inhibitors Protease Substrates Protein Kinase C Substrate KRTLRR Protein Kinase Related Peptides Protein Kinase C (19-31) Proteolipid Protein (41-58) Proteolipid Protein (184-199) Proteolipid Protein (190-209) RGDS (Fibronectin Attachment Peptide) Rimorphin SAMS Sauvagine Sauvagine and Related Peptides Sauvagine, [Tyr0]- Secretin, human Secretin, porcine Secretins SH2 Binding Domain Inhibitor SHU-9119 Somatostatin and Related Peptides Somatostatin 28 (cyclic), [Tyr0]- Somatostatin (cyclic), [Tyr0]- Somatostatin (cyclic) Somatostatin 28 (cyclic) Spantide I Substance P Antagonists Substance P, [D-Arg1,D-Trp7&9,Leu11]- Substance P, [D-Arg1,D-Phe5,D-Trp7&9,Leu11]- Substance P and Related Peptides Substance P Suc-Ala-Ala-Pro-Phe-pNA Tetracosactide Thymopentin Thymopoietin (TP) Fragments Thymosin and Fragments Thymosin-α1 Thymosin-α1, [Ac-Tyr0]- Triptorelin Urocortin, human Urocortin, rat Urodilatin Urokinase substrate, Z-γ-Glu(tBu)-Gly-Arg-pNA Urotensin II, human Urotensin II, teleost fish Urotensins Vasoactive Intestinal Peptide, human, porcine, rat, [D-Phe2]- Vasoactive Intestinal Peptide (6-28), human, porcine, rat Vasoactive Intestinal Peptide, human, porcine, rat Vasoactive Intestinal Peptide (16-28), human, porcine, rat , [pGlu16]- Vasoactive Intestinal Peptide (10-28), human, porcine, rat Vasoactive Intestinal Peptide, human, porcine, rat, [p-chloro-D-,Phe6,Leu17]- Vasoactive Intestinal Peptide (VIP) and Related Peptides Vasopressin, [d(CH2)51,D-Ile2,Ile4,Arg8,Ala9]- Vasopressin, [Lys8]- Vasopressin, [Phenylacetyl1,O-D-Tyr(Et)2,Val4,Lys6,Arg8,Tyr9]- Vasopressin, [d(CH2)51, Tyr(Me)2, Arg8]- Vasopressin, Vasotocin and Related Peptides Vasopressin, [Phe2,Lys8]- Vasopressin, [Arg8]- Vasopressin, [d(CH2)51,D-Tyr(Et)2,Arg3&8,Val4]- Vasotocin, [Arg8]- Vasotocin, [Lys8]- Vasotocin, [d(CH2)51,Tyr(Me)2,Thr4,Orn8,Tyr9]- VEGF Exon 6 Peptide VIP VIP (7-28), human, porcine, rat, Lys-Pro-Arg-Arg-Pro-Tyr- Glossary ß-Ala - ß-Alanine Aba - 2-Aminobutyric acid Ac - Acetyl Acm -  Acetamidomethyl Ada - Adamantyl AFC - 7-Amino-4-trifluoromethyl-coumaride Aha - 7-Aminoheptanoic acid Ahx - Aminohexanoic acid Aib - 2-Aminoisobutyric acid Ala - Alanine AMC - 7-Amino-4-methyl-coumaride Aph - Aminophenylalanine Arg - Arginine Asn - Asparagine Asp - Aspartic Acid Asu - 2-Aminosuberic Acid Boc - t-Butoxycarbonyl Bom - Benzyloxymethyl Bzl - Benzyl Cbz - Carbobenzoxy Cha - Cyclohexylalanine Cys - Cysteine Dab - Diaminobutyric acid DABCYL - 4-Dimethyl-amino-azobenzene-4'-sulfonyl chloride Dap - Diaminopimelic acid delta-Pro - 3.4-Dehydroproline Dnp - Dinitrophenyl Dpr - 2.3-Diaminopropionic acid EDANS - 5-[(2-Aminoethyl)amino]naphthalene-1-sulphonic acid Gln - Glutamine Glu - Glutamic Acid Gly - Glycine hCys - Homocysteine His - Histidine Hse - Homoserine Hyp - Hydroxyproline Ile - Isoleucine Leu - Leucine Lys - Lysine Mca - 7-Methoxycoumarin-4-acetyl Me - Methyl Met - Methionine Mpr - 3-Mercaptopropionyl Nal - Naphthylalanine NHEt - Ethylamide Nic - Nicotinyl Nle - Norleucine OMe - Methyl ester Orn - Ornithine OSu - Succinimide ester Pal - 2-Pyridylalanine Pen - Penicillamine pGlu - Pyroglutamic Acid Phaa - Phenylacetic acid Phe - Phenylalanine Pmp - ß-Mercapto-ß,ß-cyclopentamethylene propionic acid pNA - p-Nitroanilide Pro - Proline Sar - Sarcosine Ser - Serine Sta - Statyl- ((3S.4S)-4-amino-3-hydroxy-6-methylheptanoyl) Suc - Succinyl tBu - t-Butyl TFA - Trifluoroacetic acid Thr - Threonine Trp - Tryptophan Tyr - Tyrosine Tyr(Me) - Methyltyrosine Val - Valine Guidance Notes Storage  All peptides are supplied lyophilised to avoid degradation of the product. Most peptides if stored tightly sealed and at <-20ºC will remain stable for many years. Some peptides are stable at room temperature but it is difficult to predict so caution is sensible.  To maintain stability it is recommended that before opening, vials are warmed to room temperature in a desiccator with fresh desiccant to prevent condensation forming on the product. However, water adsorption is unavoidable for some hygroscopic or deliquescent peptides. The appearance of a peptide is usually a fluffy colourless powder but this can vary in density. Some peptides are freeze-dried to a very dense tar like form, (Usually still colourless). Others form oils. Some disappear as soon as the vial is opened, as they are deliquescent. Simply put it is impossible to judge the weight of a peptide from its appearance.  Once aliquoted peptides should be in a buffered solution pH5-7 in sterile purified water. These should be stored at <-20ºC and once reopened and thawed any remaining peptide in an aliquot should be discarded.  Dissolving  Some peptides can be very difficult to dissolve in pure water. The following measures may be taken to aid dissolution: -          Sonication to break up particles to speed up dissolution. -          A small amount of DMF or DMSO may be used to dissolve the peptide and then dilute with water. -          Most peptides are soluble in 67% aqueous acetic acid. The exceptions are usually very acidic and in these cases aqueous ammonia solution usually works. -          Addition of a chaotrope such as urea or guanidinium hydrochloride may aid dissolution of some peptides. These can interfere with biological systems so should be used sparingly.  Biological Activity  We provide a peptide with the correct amino-acid sequence, mass and purity. This does not necessarily confer the correct biological activity. Biological activity is affected by a number of factors. The peptide must have the correct conformation. This can be affected by the pH, the solvent used, trace impurities, salts, the lack of a co-factor and even the reconstitution method.  For example HIV Protease showed a greatly reduced biological activity on lyophilisation and redissolution in water. After much experimenting the following method was devised: -          Dissolve at 5mg/ml in 50mM sodium acetate, pH 5.5 containing 8M urea, 1M EDTA and 2.5mM dithiothreitol. -          To refold dilute with 9 volumes of 50mM sodium acetate pH5.5 containing 1mM EDTA and 2.5mM dithiothreitol, 10% glycerol, 5% ethylene glycol and 0.2% Non-idet P-40 at 4ºC. -          Full specific activity returned.  This is an extreme case but it is worth considering this factor if there is a reduced activity. Peptides are supplied as a salt of triflouroacetic acid and sometimes acetic acid/ammonia. As a result most have a pH of ~2-3. It is therefore necessary to neutralise the peptide and thoroughly check the pH before use as some peptides show a massive change in activity at altered pH. N.B. some peptides may have been neutralised by us if they contain an acid labile sequence, (e.g. Asp-Pro). Another important factor with pH is that if a peptide contains a cysteine in the free thiol form dimerisation can occur. This happens at its greatest rate at pH7.8. As this is in the range used for many tests rapidity is essential. In some systems the ions themselves can play a role, acetate is part of many metabolic pathways after all. If this is suspected the peptide should be desalted by passing through a desalting column such as our Super Desalting Column Plus. NOTE: WE PROVIDE A MOLECULE TO GIVEN SPECIFICATIONS. HOWEVER, EVERY PEPTIDE IS UNIQUE SO OPTIMISATION OF BIOLOGICAL ACTIVITY CAN ONLY BE DONE EXPERIMENTALLY BY THE CUSTOMER.